1

MEMORANDUM – CONFIDENTIAL PERSONNEL INFORMATION

TO: Board of Trustees

FROM: Carol L. Folt Chancellor

RE: Proposed Appointment of Executive Vice Chancellor and Provost

DATE: August 18, 2017

I seek approval for the appointment Dr. Robert A. Blouin as the University’s next Executive Vice Chancellor and Provost. The proposed appointment, if approved, will be effective September 18, 2017.

This appointment is being made due to the recent resignation of the current Executive Vice Chancellor and Provost. It is a critical time for the university as we move forward this fall on a number of significant initiatives. If we were to launch a nation-wide search process, a successful candidate would be unlikely to start until the beginning of the 2018 academic year due to the academic calendar and associated commitments to his/her respective institution. It is not in the University’s best interest to risk leaving this critical University leadership position vacant or be filled on an interim basis for the remainder of the 2017–2018 academic year.

Several critical initiatives currently underway or soon to launch require a permanent appointee in this role as soon as possible. In order to be successful, I will need to undertake a complete review of the Provost’s Office and plan to add substantial responsibilities to this position. The immediate priorities include, but are not limited to:

• University Strategic Framework, Blueprint to NextA new University Strategic Framework outlining clear university-wide priorities wasdeveloped and adopted by the Board of Trustees in January 2017. The Provost isresponsible for leading the implementation of the framework, and a number of theframework’s key initiatives are ready to be resourced and launched during the 2017-2018 academic year. It is imperative that we not lose momentum with theseuniversity-wide priorities. In particular, the Provost will be directly responsible forlaunching Extend Carolina, a strategic cross-campus collaboration to expandCarolina’s mission of high-quality education and increase access to meet changingstudent and employer needs through a diversified portfolio of online learning.

• UNC System Strategic Plan, Higher ExpectationsThe UNC Board of Governors adopted a UNC System strategic plan, HigherExpectations, in January 2017 which established metrics in nine key areas. TheProvost plays a key leadership role in the current effort of developing and confirming

ATTACHMENT A

2

UNC-Chapel Hill’s contribution to system-level targets, ensuring alignment with our institution’s strategic framework.

• University Budget Model We are mid-stream in developing an entirely new budget model that will improve the University’s process for resource management, planning and allocation. The Provost has been leading this initiative with plans for a FY 2019 implementation. Once the new budget model is refined, we will need to build the administrative processes and tools to support its integrity and long-term sustainability.

• BOG Funding Model While Carolina is evaluating its budget model, this fall, the Board of Governors Funding Model Task Force is evaluating the current system-wide enrollment based funding model. This is the first time the formula is being evaluated since 1998 and it will be critical to our financial stability. The Task Force wants to recognize the distinct missions of each UNC institution and how those differences effect the underlying cost structure of our institutions. The Provost needs to be integrally involved in these system-level deliberations.

• Ongoing NCAA Deliberations The University’s hearing with the NCAA is August 16 and 17, 2017. While the Provost will not be in attendance, he will need to be heavily involved in all subsequent actions involving the university’s response to the Amended Notice of Allegation.

• UNC-CH Capital Campaign The University will be launching a $3+ billion comprehensive capital campaign in Chapel Hill in October 2017, followed by events in New York, California, Atlanta and Florida. As the university’s chief academic officer, the Provost must be involved in all launch events, engaged in fundraising with lead donors, and advocating for key campaign priorities in support of the overall campaign.

• Carolina Service

Phase One of Carolina Service is set to launch this academic year. The Provost serves a critical role in coordinating this effort and guiding the process through to implementation. Carolina Service will restructure how finance, information technology, human resources, communications and research administration are delivered across the University, and ensure that we improve support to faculty and staff, increase accountability, and enhance efficiency.

Dr. Blouin is currently the Vaughn and Nancy Bryson Distinguished Professor, Director of the Eshelman Institute for Innovation, and has served as Dean of the UNC Eshelman School of Pharmacy at the University since July 2003. His extensive career and experience within higher education and his distinguished service at the University make him particularly well suited and highly qualified for the position of Executive Vice Chancellor and Provost at this time. He has been integrally involved with the development of the University Strategic

3

Framework, has extensive experience in the university’s research mission, and has proven to be an exceptional fundraiser. Since Dr. Blouin became dean in July 2003, the UNC Eshelman School of Pharmacy has seen significant growth and has undertaken a number of innovative initiatives. The School and its doctor of pharmacy program are ranked number one in the nation by U.S. News & World Report. Enrollment has increased by 23 percent since 2005 to approximately 650 students. A number of those students study at the School’s satellite campus in Asheville, North Carolina, which was launched in 2011. The research enterprise at the UNC Eshelman School of Pharmacy has expanded greatly during Blouin’s tenure. The School’s total research funding stood at approximately $2.2 million in 2002. By 2016, funding had grown to nearly $36 million, and the School is currently second among the nation’s pharmacy schools in total research funding. The size of the school’s facilities has nearly doubled to 315,000 square feet with the opening of the Genetic Medicine Building in 2008 and Marsico Hall in 2014. Most of the space in the new buildings is dedicated to research. The number of faculty at the School has grown by more than 70% since 2005 to nearly 110, and there are more than 100 graduate students enrolled, an increase o more than 25 percent since 2005. In 2014, thanks to Dr. Blouin’s leadership, the School received a $100 million gift from Fred Eshelman, the largest from an individual in the University’s history and the largest ever to a pharmacy school in the United States. The gift established the Eshelman Institute for Innovation, which aims to inspire a culture of innovation where imagination and creative solutions accelerate change in education, research and health care. Before coming to UNC, Blouin was a faculty member and administrator at the University of Kentucky College of Pharmacy from 1978 to 2003. Blouin last served as professor and associate dean for research and graduate education from 1997 to 2003 at the University of Kentucky College of Pharmacy. His responsibilities as associate dean included overseeing the development and expansion of the Center for Pharmaceutical Sciences and Technology, a multimillion-dollar cGMP drug formulation and manufacturing facility. As the executive director of the Office for Economic Development and Innovations Management, he served as the College of Pharmacy representative on all issues external to the University of Kentucky and those relating to economic development of the pharmaceutical sciences. He represented the college on several statewide biotechnology initiatives and has worked to advance faculty-based intellectual property. Dr. Blouin was selected as the 2016 recipient of the American College of Clinical Pharmacy’s Paul F. Parker Medal for Distinguished Service to the Profession of Pharmacy, one of the pharmacy profession’s most prestigious awards. He also received an honorary degree from the Monash University in Melbourne, Australia in May 2017. Dr. Blouin’s impressive track record at the Eshelman School of Pharmacy and as the leader of a number of university-wide initiatives, his extensive relationships with faculty and staff throughout the university, his experience as an educator, research, innovator and

4

administrator, and his reputation through the state, region and country make him the best choice to serve as the next Executive Vice Chancellor and Provost for UNC-Chapel Hill. The proposed annual salary for Dr. Blouin is $469,742. Dr. Blouin’s present base salary is $291,079 plus an administrative supplement of $25,000 for serving as Dean, and an administrative supplement of $41,764 for serving in the secondary appointment of Director of the Eshelman Institute for Innovation. The newly proposed total compensation request represents a 61.38% increase from his current base salary of $291,079, and a 31.27% increase from his current total compensation amount of $357,843. The Board is asked to approve both Dr. Blouin’s appointment to Executive Vice Chancellor and Provost, a Tier I SAAO, and his proposed new salary amount. All of Dr. Blouin’s terms and conditions of employment are standard for Senior Officers of this rank in accord with the University’s EHRA Non-Faculty Employment Policies. I am attaching a copy of Dr. Blouin’s CV for your information. I look forward to answering any questions you may have regarding Dr. Blouin’s proposed appointment, as I believe Dr. Blouin will continue to make a substantial and long-lasting contribution to our University in this new capacity. Presuming your approval, Dr. Blouin’s proposed salary increase is then subject to final approval by the UNC Board of Governors.

1

CURRICULUM VITAE ROBERT A. BLOUIN

(Revised July 2017) GENERAL INFORMATION Home Address: 102 Lake Manor Road Chapel Hill, NC 27516 (919) 218-5611 (cell) Office Address: UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill CB# 7355, 100C Beard Hall Chapel Hill, NC 27599-7355 (919) 966-1122 (Office) (919) 966-6919 (Fax) E-mail: bob_blouin@unc.edu EDUCATION 1975 Bachelor of Science: Massachusetts College of Pharmacy (Pharmacy) Boston, Massachusetts 1978 Doctor of Pharmacy: College of Pharmacy University of Kentucky Lexington, Kentucky 1975-78 Residency: University of Kentucky Medical Center Lexington, Kentucky PROFESSIONAL EXPERIENCE 1978-1984 Assistant Professor, University of Kentucky, College of Pharmacy Director, Clinical Pharmacokinetics Program, University of Kentucky Medical Center 1984-1989 Associate Professor, University of Kentucky, College of Pharmacy, Clinical Practice Division 1984-2003 University of Kentucky Graduate Faculty (Full Member) 1984-1989 Associate Director, Drug Product Evaluation Program 1985-2003 Member, Toxicology Graduate Faculty 1985-1988 Member of Core Faculty, Geriatric Education Center Grant 1986-2003 Member, Lucille Parker Markey Cancer Center 1987-1988 Sabbatical, F. Hoffmann-LaRoche, Basel, Switzerland 1987-1998 Director, Clinical Pharmacology Program 1989-2003 Professor, University of Kentucky, College of Pharmacy, Division of Pharmacology and Experimental Therapeutics 1994-1996 Director, Summer Minority Undergraduate Research Program in Clinical Pharmacology 1997-2003 Associate Dean for Research and Graduate Education 2001-2003 Executive Director - Economic Development and Innovations Management 2003- Dean, Vaughn and Nancy Bryson Distinguished Professor, UNC Eshelman School of Pharmacy The University of North Carolina at Chapel Hill 2015- Director, Eshelman Institute for Innovation

2

2009- Co-founder: Infoporte Solutions – Software development company supporting academic institutions human resource, business and finance, and grant and contract business needs. First launch of InfoporteTM occurred in the summer of 2009 at The University of North Carolina at Chapel Hill.

2012 Harvard Macy Institute: Program for Leading Innovations in Health Care and Education, Harvard Medical School, June 10-15, 2012

ADMINISTRATIVE EXPERIENCE Summary of Administrative Activities as Dean at the University of North Carolina Dean (July 2003 – present): This position reports directly to the Provost and serves as the primary Chief Executive Officer of the UNC Eshelman School of Pharmacy. The UNC Eshelman School of Pharmacy has experienced unprecedented growth in its research and education programs over the past fourteen years and is consistently ranked amongst the top academic pharmacy programs in the world. The School is currently ranked #1 by US News & World Report ranking US Pharmacy Schools, #1 by TFE Times ranking US Pharmacy Schools, #2 by US News & World Report ranking of Global Universities under the subject area of Pharmacology and Toxicology, and #10 by QS World University Rankings under the subject area of Pharmacy and Pharmacology programs. The School successfully launched an innovative satellite professional degree-granting program in Asheville, NC. The School’s Educational Renaissance initiative has received critical acclaim throughout the pharmacy academic community and is being used as an exemplary education model on the UNC-CH campus and beyond. Summary of Administrative Activities as Director of the Eshelman Institute for Innovation (December 2014 – present): This position reports to the Steering Committee of the Eshelman Institute for Innovation, a school-based center of the UNC Eshelman School of Pharmacy. As with all centers and institutes at the University of North Carolina at Chapel Hill, this center is also subject to University and Board of Governors oversight. The Institute was established to accelerate the creation and development of ideas leading to discoveries and high impact changes in education, research and health care. On December 3, 2014, the University of North Carolina at Chapel Hill announced a $100 million commitment from Dr. Fred Eshelman, the largest gift from an individual in the history of the university, to create the Eshelman Institute for Innovation at the UNC Eshelman School of Pharmacy. Summary of Administrative Activities at the University of Kentucky Associate Dean for Research and Graduate Education (1997 – 2003): This position reported directly to the Dean of the College of Pharmacy and served as the primary College interface with the Vice President for Research (University of Kentucky) and Associate Vice President for Research and Graduate Studies (A.B. Chandler Medical Center). During this period, the College of Pharmacy made significant progress in securing competitive research funding, nearly tripling its grant and contract portfolio from federal and industrial sponsors. The College was the first in the country to launch a graduate program in the clinical pharmaceutical sciences (1987); a program that remains a model among pharmacy programs across the country. In addition, the College of Pharmacy emerged as a campus leader in the creation of intellectual property and company spin-offs. The Office of the New Economy (direct report to the Governor of the Commonwealth of Kentucky) worked very closely with the College of Pharmacy and supported the development and construction of the Center for Pharmaceutical Science and Technology. This facility became a cornerstone in the University of Kentucky’s Coldstream Research Campus. Executive Director of the Office for Economic Development and Innovations Management (2000 – 2003): This position reported directly to the Dean of the College of Pharmacy and served as the College of Pharmacy representative in all issues external to the University of Kentucky relating to matters of economic development of the pharmaceutical sciences. Interactions primarily consisted of working with the Commissioner of the Office for the New Economy (Frankfort, Kentucky), Kentucky Council on

3

Postsecondary Education (Frankfort, Kentucky), Kentucky Economic Development Authority (Frankfort, Kentucky), Lexington Chamber of Commerce (Lexington, Kentucky), Kentucky Science and Technology Corporation “The Innovation Group”, and Lexington United (Lexington, Kentucky). Director, Clinical Pharmaceutical Sciences Graduate Training Program (1987 – 1998): This position was responsible for the creation and development of a graduate training track at the Ph.D. level in the Clinical Pharmaceutical Sciences at the University of Kentucky College of Pharmacy. This program was the first of its kind and has since trained over 30 graduate students to date who have pursued careers in academia, industry, and government. TEACHING ACTIVITY PRIMARY RESPONSIBILITIES: PHR 875 Clinical Pharmacokinetics PHR 760 Special Problems PHR 895 Independent Problems PHR 848 Pharmacy Practice III PHR 947 Applied Biopharmaceutics and Pharmacokinetics - Primary Responsibility PHR 760 Introduction to Clinical Pharmacology SECONDARY RESPONSIBILITIES: PHR 876/878 Advance Pharmacotherapeutics PHR 868 Pharmacotherapeutics PHR 802 Pharmaceutics PHR 884 Pharmacy Practice Clerkship TOX/PAT 660 Clinical Toxicology and Drug Monitoring PAT 821 Laboratory Medicine Case Studies PHR 870 Clinical Orientation Clerkship PHR 612 Advanced Pharmacokinetics PHR 770 Proseminar in Toxicology TOX 680 Advanced Toxicology PHA 663 Drug Metabolism and Disposition ADVISING ACTIVITY

GRADUATE STUDENTS Student Role 1978-1983 Kim Rowse Brouwer Co-Advisor 1984-1988 Philip Dickson (Toxicology) Advisor 1986-1989 Inder Chaudhary (Toxicology) Advisor 1987-1991 Philip Colangelo Advisor 1988-1993 Steve Toler Advisor 1989-1993 Somsong Tuntaterdtum (Toxicology) Advisor 1988-1993 Peter Zannikos Advisor 1988-1994 Karen Nishihara Advisor 1992-1997 Ming Lu Advisor 1993-1997 Amy Roe (Toxicology) Advisor 1995-1997 Lihong Peng Co-Advisor

4

1994-1999 Kevin Rockich Advisor 1996-1999 Graham Warren (Toxicology) Advisor 1996-1999 Samuel Poloyac Advisor 1998-2002 Peter Van Ess Advisor 1982-1984 William Fiske Dissertation Committee Member 1982-1986 Kenneth Brouwer Dissertation Committee Member 1983-1986 Scott Hamann (Toxicology) Dissertation Committee Member 1983-1988 Sabah Akrawi Dissertation Committee Member 1985-1990 Roxanne Jewell Dissertation Committee Member 1986-1991 Hussein Hallak Dissertation Committee Member 1987-1991 Mary Freeman (Chemistry) Dissertation Committee Member 1988-1990 Yolanda Poppell Dissertation Committee Member 1988-1990 Neil Hoglen (Toxicology) Dissertation Committee Member 1989-1992 Renli Teng Dissertation Committee Member 1990-1997 Richard Page Dissertation Committee Member 1991-1996 David Burgio Dissertation Committee Member 1992-1997 Naresh Punwani Dissertation Committee Member 1992-1994 James Meece (Toxicology) Dissertation Committee Member 1992-1995 Ujjwala Samant Dissertation Committee Member 1992-1995 Sujatha Thampi (Toxicology) Dissertation Committee Member 1992-1996 Cheach Yee Oo Dissertation Committee Member 1992-1997 Yinzi Tang Dissertation Committee Member 1993-1997 Greg Oakley (Toxicology) Dissertation Committee Member 1995-1997 William Allan Rees (Toxicology) Dissertation Committee Member 1996-2002 Mathew Cooper (Toxicology) Dissertation Committee Member 1996-2003 Philip Gerk Dissertation Committee Member 1997-2001 Brian Laden Dissertation Committee Member 1998-2002 Gerome V. Burke Dissertation Committee Member 1998-2002 Jane Alcorn Dissertation Committee Member 1998-2002 Nilufer Tampal (Toxicology) Dissertation Committee Member 1999-2002 Leigh Verbois Dissertation Committee Member 1999-2000 Chris Cunningham Dissertation Committee Member 2001-2007 Philip Empey Dissertation Committee Member POST-DOCS AND VISITING SCIENTISTS 1985-1987 Mary H.H. Chandler Post-Doctoral Fellow - Pharmacokinetics 1987-1989 Deborah A. Smith Post-Doctoral Fellow - Pharmacokinetics 1989-1990 Ye Songbai Visiting Scientist - Pharmacology 1989-1991 Inder Chaudhary Post-Doc. Fellow - Pharmacokin./Toxicol. 1990-1991 Bettina L. Hamelin Post-Doctoral Fellow - Pharmacokinetics 1991-1993 Beth Israel Post-Doctoral Fellow - Pharmacokinetics 1989-1993 Abhik Bandyopadhyay Post-Doctoral Fellow - Molecular Biology 1996-1998 Angela Watson Post-Doctoral Fellow - Toxicology 1999-2000 Asad Abrahamian Post-Doctoral Fellow - Toxicology

5

UNIVERSITY SERVICE COLLEGE COMMITTEES: Administrative Council Research and Graduate Program – Ex-Officio Student Affairs Committee Nominations Committee Appointment, Promotion, and Tenure (Chairman) ACPE Evaluation Committee Curriculum Committee Task Force on Professional Programs (Chairman) Residency Advisory Committee Center for Pharmaceutical Sciences at Coldstream Building Committee Safety and Space College Executive Committee Pharmaceutical Sciences Executive Committee - Ex-Officio MEDICAL CENTER COMMITTEES: American Cancer Society Institutional Research Academic Council Medical Center IACUC Medical Center Subcommittee Vice Chancellor for Research and Graduate Studies: Search Committee Executive Committee, Graduate Center for Toxicology Graduate Center for Toxicology Training Grant Committee Graduate Center for Toxicology Admission and Finance Committee Medical Center Clinical Sciences Area Advisory Committee Graduate Center for Toxicology Academic Performance and Progress Committee Medical Center Research Advisory Committee Radiation Safety Committee UNIVERSITY COMMITTEES: University of North Carolina Big Ideas Committee (Committee Chair) The Lincoln Project (Member) Health Informatics Oversight Committee (Member) Dean’s Council (Member) Clinical Translational Internal Advisory Board (Member) NC TraCS Internal Advisory Board (Member) UNC/Duke Collaborative Clinical Pharmacology Postdoctoral Training Program (T32) External Advisory Board University Cancer Research Fund Oversight Committee (Member) University Cancer Research Fund Executive Committee (Member) UNC School of Medicine Liaison Committee on Medical Education (Member) Pharmacy Foundation of North Carolina Executive Committee (Member) UNC Campaign Planning Committee (Member) Associate Vice-Chancellor for Research Search Committee (Member) Dean, School of Nursing Search Committee (Committee Chair) Carolina First Campaign Steering Committee (Member) Task Force on Campus-wide Support Needs for Technology Mediated Teaching and Learning (Member)

6

A Su Salud Advisor Board (Member) UNC Engagement Task Force (Member) UNC Tomorrow: Task Force on Economic Transformation and Community Development (Member) Kenan Institute Strategic Planning Advisor Board (Member) Chair, UNC Eshelman School of Pharmacy Executive Committee (Member) UNC Naming Committee (Member) UNC Biomedical Research Imaging Center Advisory Committee (Member) North Carolina Pharmacy Foundation Board (Ex Officio Member) General Counsel Search Committee, (Member) UNC Catalyst Board (Chair) Strategic Framework Subcommittee: An experiential-active-learning/educational transformation initiative

connecting all schools with unifying goals and outcomes (Co-Chair) UNC Global Leadership Council (Member) Arts and Science Strategic Planning Committee (Member) University of Kentucky Technical Advisory Committee of the Tobacco and Health Research Institute University Self Study Research Subcommittee Undergraduate Council Graduate Council Committee on Fellowship and Traineeships Scientific Misconduct Review Committee University Research Advisory Committee Kentucky Center for Clinical Research and Investigator Services Advisory Committee Biomedical/Biological Sciences Research Building Planning Committee Intellectual Property Committee CPST Building Committee, Chairman Task Force on Biocomputing Lexington’s Technology’s Visioning Committee Program Review - Graduate Center for Toxicology Program Review - Research and Graduate Studies Administrative and Fiscal Affairs University of Kentucky Research Foundation Board of Directors University of Kentucky Futures Task Force SPECIAL ASSIGNMENTS / PRESENTATIONS 1983-84 SIG on Clinical Pharmacokinetic Practice - Chairman 1983-91 ASHP Research and Education Foundation's Selection Panel for the Fellowship in Clinical Pharmacokinetics 1988-90 Member - ASHP Council on Professional Affairs 1989 Member - Astra Clinical Pharmacy Research Award, Grant Selection Committee 1989 Alternate Member - ASHP Foundation Advisory Committee 1989-90 ACCP Research Affairs Committee 1990 VA Merit Award Reviewer 1990-95 USP Advisory Panel on Geriatrics 1990-92 University of Pittsburgh College of Pharmacy Advisory Committee 1990 ASHP Committee on Guidelines for Research Presentation at SPG Meetings 1991 Advisor, Geriatric Pharmacy Institute, Philadelphia College of Pharmacy 1991-92 ASHP Foundation Strategic Planning Team 1992-94 Elected, ACCP Research Institute Trustee

7

1992 VA Merit Award Reviewer 1995 Participation in Glaxo/AACP New Dean’s Leadership Institute 1998 Participation in the University of Kentucky Leadership Certificate Course 1999 Scientific Reviewer - Indiana 21st Century Research and Technology Fund 2000 BIO2001 Conference: Biotechnology Kentucky 2000 BIO2001 Conference: Planning Committee 2000 IDeA Workshop: Planning Institutional Grant Submission 2000-03 ACCP Research Institute Trustee 2001-02 ACCP Strategic Planning Committee 2001-03 ACCP Research Institute Fellowship Task Force 2004 Chair, State Employees Combined Campaign (SECC) 2004 NIH Road Map Committee, Member 2005 Administrative Review of the Position of Vice Chancellor for Finance and Business (Chair) 2005 External Advisory Board, Massachusetts College of Pharmacy and Health Sciences 2006 AACP Research & Graduate Affairs Committee 2006 IHI Health Professionals Education Collaborative 2006 AACP Task Force on Clinical Sciences – T1, Chair 2006 Participation in PharmD Pathways to Biomedical Research 2007 ACPE Rutgers Site Visit Team 2007 University of North Carolina CTSA Advisory Committee (present) 2007 Texas Tech Site Visit Team 2007 AACP Educating Clinical Scientists Task Force – T2 2007 University Cancer Research Fund Governance Board (present; legislative mandate) 2008 University of Wisconsin Institute for Clinical and Translational Research External Advisory Committee 2008-present AACP-ALFP (Dean mentor) 2009 University of North Texas Feasibility Committee for a New School of Pharmacy

(Chairman) 2011 Good to Great at Carolina: A Conversation with Chancellor Emeritus James Moeser http://www.youtube.com/watch?v=s7DfDEkyNDo 2012-present Frank Hawkins Kenan Institute for Private Enterprise Advisory Board (UNC) 2012-present AACP Research and Graduate Affairs Advisory Committee (Chairman) 2013-present Advisory Board for the University of North Texas College of Pharmacy 2013-present ACCLAIM Program Retreat Leadership Panel (UNC) 2013-present AACP Chair-Elect Council of Deans 2013-2014 AACP-ACPE Standards Revision Committee 2013-2014 AACP Chalmers Award Review Committee 2014 AACP Strategic Planning Committee 2015-present AACP Member of Board of Directors 2015-present Structural Genomic Consortium Board (Representative Member) 2016-present Macy Conference Planning Committee

8

HONORS/AWARDS Pharm.D. Resident Impact Award - 1978 Rho Chi Pharmacy Honor Society Fellow - American College of Clinical Pharmacy - 1991 University of Kentucky College of Pharmacy Outstanding Second Year Professor Award - 1997 University of Kentucky College of Pharmacy B.Sc. Senior Class Award - 1997 University of Kentucky College of Pharmacy Doctor of Pharmacy Senior Class Award - 1997 University of Kentucky College of Pharmacy Outstanding Second Year Professor Award - 1998 University of Kentucky College of Pharmacy Doctor of Pharmacy Senior Class Award - 1998 University of Kentucky College of Pharmacy Doctor of Pharmacy Senior Class Award - 1999 University of Kentucky College of Pharmacy Outstanding Second Year Professor Award - 2000 University of Kentucky College of Pharmacy Doctor of Pharmacy Senior Class Award - 2000 Fellow - American Association for Pharmaceutical Scientists - 2001 University of Kentucky College of Pharmacy Doctor of Pharmacy Senior Class Award - 2002 Paul F. Parker Award – 2003 The 11th Annual Michael J Ordman Memorial Lecture, Massachusetts College of Pharmacy and Health Sciences 2007 Massachusetts College of Pharmacy’s 2011 Rho Chi Lecturer University of Tennessee’s 2009 First Tennessee Chair of Excellence Distinguished Visiting Professor University of Kentucky’s 2009 Rho Chi Lecturer Ohio State University’s 2012 Rho Chi Lecturer 2012 Milap Nahata Distinguished Lecturer Award 2013 Krantz Lecturer, University of the Sciences 2015 Graduation Speaker – University of California at San Diego Skaggs School of Pharmacy and

Pharmaceutical Sciences 2015 University of Kentucky College of Pharmacy Hall of Distinguished Alumni Award 2015 NCAP Blanton Award for Pharmacy Contributions 2016 University of North Carolina General Alumni Association Faculty Service Award 2016 University of Michigan’s Dean’s Leadership Series Lecturer 2016 ACCP Parker Medal 2017 Robert G. Leonard Memorial Lecture Award 2017 Barry L. Reed Distinguished Lecturer 2017 Awarded – Doctor of Laws honoris causa from Monash University PROFESSIONAL ACTIVITY AND PUBLIC SERVICE SCIENTIFIC AND PROFESSIONAL SOCIETY MEMBERSHIPS: American College of Clinical Pharmacy American Association of Pharmaceutical Scientists American Pharmacists Association American Association of Colleges of Pharmacy American Society of Health-System Pharmacists North Carolina Association of Pharmacists

9

JOURNAL REFEREE: American Journal of Hospital Pharmacy Drug Intelligence and Clinical Pharmacy Clinical Pharmacy Pharmacotherapy Journal of Pharmaceutical Sciences Clinical Pharmacokinetics Newsletter Clinical Pharmacokinetics Journal of Geriatric Drug Therapy Clinical Chemistry Pharmaceutical Research Biopharmaceutics and Drug Disposition International Journal of Obesity Drug Metabolism and Disposition Journal of Pharmacology and Experimental Therapeutics Biochemical Pharmacology Journal of Biopharmaceutics and Pharmacokinetics Pharmaceutical Development and Technology Canadian Journal of Physiology and Pharmacology EDITORIAL BOARDS: Clinical Pharmacokinetics Newsletter Journal of Geriatric Drug Therapy Pharmacotherapy

10

SPEAKING ENGAGEMENTS

ABSTRACTS/POSTERS/PRESENTATIONS: 1. Blouin RA: "Development of a Clinical Pharmacokinetics Drug Monitoring Program", Medical

University of South Carolina, Charleston, SC, October 1978 (presentation). 2. Blouin RA: "Clinical Pharmacokinetics - Concepts in Theophylline Monitoring", Hamot Medical

Center, Erie, PA, November 1978 (presentation). 3. Blouin RA: "Obtaining Third Party Reimbursement for Clinical Services: A Panel Discussion", 13th

Annual ASHP Midyear Clinical Meeting, San Antonio, TX, December 1978 (presentation). 4. Blouin RA: "Rational Use of Drug Blood Levels", Northwestern Society of Hospital Pharmacists, Erie,

PA, November 1978 (presentation). 5. Blouin RA: "Application of Drug Blood Levels in the Clinical Setting", Southeast Kentucky Baptist

Hospital Medical Staff Conference, Corbin, KY, January 1979 (presentation). 6. Blouin RA: "Theophylline Pharmacokinetics", Ohio Society of Hospital Pharmacists Mansfield, OH,

June 1979 (presentation). 7. Blouin RA: "The Pharmacist and the Asthmatic Patient", Kentucky Society of Hospital Pharmacists,

Louisville, KY, May 1979 (presentation).

8. Blouin RA, Foster TS, Smith RB, and Kostenbauder HB: "Multidisciplinary Approach Towards the Teaching of Clinical Pharmacokinetics", AACP Annual Meeting, Denver, CO, July 1979 (poster).

9. Blouin RA: "Aminoglycoside Pharmacokinetics", Morehead Clinic, Morehead, KY, October 1979

(presentation). 10. Dutro MP, Blouin RA, Erwin WG, Bustrack JA, Rowse KL: "Chloramphenicol Clearance and Protein

Binding During Hemodialysis", ASHP Midyear Clinical Meeting, Las Vegas, NV, December 1979 (poster).

11. Dionne RE, Gibson GA, Bauer LA, Blouin RA, and Griffen WO: "Evaluation of Methods to Estimate

Creatinine Clearance in Morbidly Obese Patients", ASHP Midyear Clinical Meeting, Las Vegas, NV, December 1979 (poster).

12. Blouin RA, Bauer LA, Griffen WO., Jr., Record KE, and Bell RM: "Amikacin Pharmacokinetics in

Morbidly Obese Patients", ASHP Midyear Clinical Meeting, Las Vegas, NV, December 1979 (presentation).

13. Blouin RA: "Theophylline Pharmacokinetics", Hunter Foundation for Health Care, Lexington, KY, May

1980 (presentation). 14. Blouin RA: "Bioavailability of Drugs and Clinical Pharmacokinetics", The Institute of Applied

Pharmaceutical Science, East Brunswick, NJ, July 1980 (presentation).

11

15. Oeltgen PR, Hamann SR, Blouin RA: "Comparison of RIA and Emit for the Determination of Serum Gentamicin", American Association for Clinical Chemistry Annual Meeting, Boston, MA, July 1980 (abstract).

16. Bauer LA, Bauer SP, Blouin RA: "Theophylline Clearance in Cigarette Smoking Patients with Renal

Failure", ASHP Midyear Clinical Meeting, San Francisco, CA, December 1980 (poster). 17. Blouin RA: "How to Develop and Implement a Clinical Pharmacokinetic Service", ASHP Institute,

Atlanta, GA, March 1981 (presentation). 18. Blouin RA: "The Laboratory's Role in Therapeutic Drug Monitoring - Pharmacokinetics in Clinical

Practice", University of Kentucky, College of Allied Health Professions, Lexington, KY, May 1981 (presentation).

19. Blouin RA: "Acetaminophen Overdose" Medicine Conference, St. Joseph's Hospital, Lexington, KY,

October 1981 (presentation). 20. Blouin RA: "Application of Clinical Pharmacokinetics of Theophylline", Third Annual Open Forum,

Toledo, OH, November 1981 (presentation). 21. Blouin RA: "Development of a Theophylline Pharmacokinetic Service", Fourteenth Annual Expanding

Hospital Pharmacy Services Seminar, Toledo, OH, November 1981 (presentation). 22. Rowse KL, Blouin RA, Record KE, Griffen WO, John W: "Effect of Surgery on the Pharmacokinetics

of Amikacin in Morbidly Obese Patients", ASHP Midyear Clinical Meeting, New Orleans, LA, December 1981 (poster).

23. Blouin RA: "How to Develop and Implement a Clinical Pharmacokinetics Service", ASHP Institute,

Cleveland, OH, August 1982 (presentation). 24. Blouin RA: "Management of the Aged: Pharmacokinetic Considerations" ASHP Midyear Clinical

Meeting, Los Angeles, CA, December 1982 (presentation). 25. Bauer LA, Blouin RA: "Phenytoin Michaelis - Menten Kinetics in Caucasian Pediatric Patients",

American Society for Clinical Pharmacology and Therapeutics, San Diego, CA, March 1983 (poster). 26. Fiske WD, Blouin RA, McNamara, PJ: "P-aminohippurate and Glucose Interaction", APhA Annual

Meeting, New Orleans, LA, April 1983 (poster). 27. Benedek IH, Fiske WD, Griffen WO Jr., Blouin RA, McNamara PJ: "Serum Protein Binding of Drugs

and Obesity", APhA Annual Meeting, New Orleans, LA, April 1983 (poster). 28. Rowse KL, Kostenbauder HB, McNamara PJ, Blouin RA: "Pharmacokinetics of Phenobarbital in Obese

Zucker, Lean Zucker and Sprague-Dawley Rats", APhA Annual Meeting, New Orleans, LA, April 1983 (poster).

29. Blouin RA: "Introduction to Pharmacokinetics", Bristol Laboratories, Syracuse, NY, July 1983

(presentation).

12

30. Mays-Whitten K, O'Neal W, Piecoro J, Baumann R, Blouin RA: "Carbamazepine Overdosage: A Case Report", ASHP Midyear Clinical Meeting, Atlanta, GA, December 1983 (poster).

31. Blouin RA: "Aminoglycoside Antibiotics", Seventeenth Annual Southwestern Clinical Pharmacy

Seminar, Tucson, AZ, February 1984 (presentation). 32. Blouin RA: "Consulting Services and New Technologies", Seventeenth Annual Southwestern Clinical

Pharmacy Seminar, Tucson, AZ, February 1984 (presentation). 33. Hamann SR, Blouin RA, Kaltenborn KE, McAllister RG: "Plasma Level - Dependent Clearance of

Verapamil During Intravenous Infusion", American Society for Clinical Pharmacology and Therapeutics, Atlanta, GA, April 1984 (abstract).

34. Rowse Brouwer KL, Kostenbauder HB, McNamara PJ, Blouin RA: "Hepatic Drug Metabolism in a

Genetically Obese Rodent Model: Altered Response to Phenobarbital (Pb) Treatment", FASEB, St. Louis, MO, April 1984 (abstract).

35. Benedek IH, Blouin RA, McNamara PJ: "Altered Drug Protein Binding in the Serum of a Genetically

Obese Zucker Rat", APhA Meeting, Philadelphia, PA, November 1984 (poster). 36. Barton SD, Mohler J, Blouin RA, Rapp RP: "Creatinine Production in Spinal Cord Injured Patients",

OCCP & CP, Cincinnati, OH, November 1984 (poster). 37. Blouin RA: "Pharmacokinetic Considerations of the Post-Operative and Burned Patient", California

Society of Hospital Pharmacists, San Francisco, CA, November 1984 (presentation). 38. Blouin RA: "Pharmacokinetics Considerations of the Post-Operative and Burned Patient", California

Society of Hospital Pharmacists, Los Angeles, CA, November 1984 (presentation). 39. Michael KA, Mohler JL, Blouin RA, Lucas BA, Rapp RP: "Failure of Creatinine Clearance to Predict

Gentamicin Half-Life in a Renal Transplant Patient: A Descriptive Report", ASHP Midyear Clinical Meeting, Dallas, TX, December 1984 (poster).

40. Blouin RA, Fiske WD, McNamara PJ: "Renal Function in the Genetically Obese Zucker Rat", FASEB,

Anaheim, CA, April 1985 (accepted). 41. Blouin RA: "Renal Function in Obesity - Clinical Implications", Research and Seminar Series, Augusta,

GA, February 1985 (presentation). 42. Blouin RA: "Biopharmaceutic and Pharmacokinetic Considerations of Drug Product Selection", Virginia

Society of Hospital Pharmacists, Richmond, VA, November 1985 (presentation). 43. Kolpek J, Blouin RA, Parr M: "Alteration in Creatinine Production Rates in Cushingoid Patients", ASHP

Midyear Clinical Meeting, New Orleans, LA, December 1985 (poster). 44. Foster TS, Blouin RA, Hobbs S, McAllister RG: "Dose Proportionality of Nifedipine: A Single

Escalating Intravenous Dose Study in Man", ACCP, Chicago, IL, July 1986 (poster).

13

45. Blouin RA, McNamara PJ, Dickson P, McClain C, Cibull M: "Resistance to Acetaminophen Hepatotoxicity in the Obese Zucker Rodent", AAPS, Washington, DC, November 1986 (poster).

46. Chandler MHH, Guttendorf RJ, Wedlund PJ, Blouin RA: "Simultaneous Quantitation of d- and l-

Hexobarbital in Rat Blood by High Performance Liquid Chromatography", AAPS, Washington, DC, November 1986 (poster).

47. McNamara PJ, Blouin RA, Brazzell RK: "Drug Protein Binding in Diabetic and Non-Diabetic Serum",

AAPS, Washington, DC, November 1986 (poster). 48. McNamara PJ, Blouin RA, Brazzell RK: "Serum Protein Binding of ALO1576, A New Aldose

Reductase Inhibitor", AAPS, Washington, DC, November 1986 (poster). 49. Blouin RA: Overview of Drug Pharmacology in the Elderly, "Life After Fifty Gerontology Fair",

Bowling Green, KY, September 1986 (presentation). 50. Blouin RA: "Clinical Pharmacokinetic Monitoring: Past, Present and Future", KSHP, Louisville, KY,

May 1987 (presentation). 51. Guttendorf RJ, Chandler MHH, Blouin RA, Wedlund PJ: "Effect of Age on Hexobarbital Stereoselective

Disposition in the Rat", AAPS, Boston, MA, June 1987 (poster). 52. Guttendorf RJ, Blouin RA, Foster TS, Wedlund PJ: "Dextromethorphan Mephenytoin: Influence of Co-

Administration on Patient Phenotyping", AAPS, Boston, MA, June 1987 (poster). 53. Chandler MHH, Schran HF, Proskin HM, Gonasun LM, Smith AJ, Foster TS, Hobbs SN, Blouin RA:

"Effects of Renal Function on the Disposition of Isradipine" ACCP, Austin, TX, July 1987 (poster). 54. Blouin RA: "Clinical Complications in Drug Dosing", Kentucky Academy of Family Physicians,

Owensboro, KY, July, 1987 (presentation). 55. Chandler MHH, Scott SC, Blouin RA: "Age-Dependent Stereoselective Alterations in Hexobarbital

Metabolism", American Society of Clinical Pharmacology and Therapeutics, San Diego, CA, March 1988 (poster).

56. Jones P, Chaudhary I, Robertson L, Blouin RA: "Molecular Basis of Inducibility of cyt P-450 in Obese

Rodent Model", Society of Toxicology, Dallas, TX, February 1988 (poster). 57. Chaudhary I, McNamara PJ, Blouin RA: "Acetaminophen Hepatotoxicity in Obese Zucker Rats:

Mechanism of Resistance", Society of Toxicology, Dallas, TX, February 1988 (poster). 58. Blouin RA, Stoeckel K: "Pharmacokinetic Comparison of Fluoroquinolones", International Congress for

Infectious Disease, Rio de Janeiro, April 1988. 59. Kneer J, Blouin R, Keller E, Stathakis C, Stoeckel K: "Pharmacokinetics of Cefetamet in Patients with

Renal Insufficiency", 6th Mediterranean Congress of Chemotherapy, Taormena-Giardini Naxos, Italy, May 1988 (poster).

14

60. Chaudhary I, McNamara PJ, Blouin RA: "Effect of Phenobarbital Induction on Acetaminophen Kinetics in Obese Zucker Rat", AAPS, Orlando, FL, November 1988 (poster).

61. Blouin RA, Foster TS, Wedlund PJ, John W, Kolpek J, Robbins D, Cox SR: "Drug Metabolism of

Flurbiprofen Enantiomers in Liver Disease", AAPS, Orlando, FL, November 1988 (poster). 62. Blouin RA: "Age Related Stereoselective Alterations in Hexobarbital Metabolism", Idaho State

University, Pocatello, ID, November 1988 (seminar). 63. Blouin RA: "Clinical Scientists: Are They Needed?" Idaho State University, Pocatello, ID, November

1988 (seminar). 64. Chandler MHH, Clifton GD, Blouin RA, Hunt BA, Burki NK: "Pulmonary Function in Elderly:

Response to Theophylline Bronchodilation", ASCPT, Nashville, TN, March 1989 (poster). 65. Chaudhary I, Robertson L, Blouin RA: "Enzyme Induction Defect to Phenobarbital in the fa/fa Zucker

Rat: Relation Between Cytochrome P-450 and UDPGT", SOT, Atlanta GA, March 1989 (poster). 66. Chen LC, Chaudhary I, Blouin RA, Chow CK: "Effect of Acetaminophen on Hepatic Antioxidant Status

of Zucker Rats", FASEB, New Orleans, LA, March 1989 (poster). 67. Smith DA, Chandler MHH, Shedlofsky S, Wedlund PJ, Blouin RA: "Stereoselective Induction of

Hexobarbital with Rifampin", ASCPT, Nashville, TN, March 1989 (poster). 68. Blouin RA: "Relevance of Animal Models to Human Pharmacokinetics: An Example", ASCPT

Symposium on Pharmacokinetics and Pharmacodynamics, Nashville, TN, March 1989 (Symposia presentation).

69. Blouin RA, Smith DA, Chandler MHH, Shedlofsky SI, Wedlund PJ: "The Effects of Rifampin

Treatment on the Stereoselective Metabolism of Hexobarbital in Young and Elderly Subjects", IV World Conference in Clinical Pharmacology & Therapeutics, Heidleberg, Germany, July, 1989 (poster).

70. Blouin RA: "Stereoisomerism - Practical Considerations", ACCP Symposium on Drug Stereochemistry:

What the Science Means to the Clinician, Kansas City, MO, August 1989. 71. Blouin RA: "Clinical Scientist Program", ACCP, Kansas City, MO, August 1989 (roundtable

discussion). 72. Smith DA, Chandler MHH, Shedlofsky SI, Wedlund PJ, Blouin RA: "The Effects of Rifampin Induction

on the Stereoselective Metabolism of Hexobarbital in the Young and Elderly", ACCP, Kansas City, MO, August 1989 (presentation).

73. Foster TS, Blouin RA: "The Effect of Antacid Timing on Lomefloxacin Bioavailability", Houston, TX,

September 1989 (poster). 74. Blouin RA: "Influence of Obesity on Xenobiotic Metabolism", Ohio Valley Society of Toxicology,

Cincinnati, OH, May 1989 (Symposia presentation).

15

75. Kneer J, Tam YK, Blouin RA, Stoeckel K: "The Influence of Food and Fluid Intake on the Absorption of Cefetamet Pivoxil", International Congress of Chemotherapy, Jerusalem, Israel, June 1989 (poster).

76. Wedlund PJ, Zhang Y, Britto M, Blouin RA, McNamara PJ, Steinmetz J, DeMaria AN: "Polymorphic

Oxidative Metabolism of S-Mephenytoin", ASCPT, San Fransisco, CA, March 1990 (poster). 77. Colangelo P, Blouin RA, McNamara PJ, Wedlund PJ, Steinmetz J, Demaria AN: "Age and Its Effect on

Propranolol Stereoselective Oral Clearance", ASCPT, San Fransisco, CA, March 1990 (poster). 78. Blouin RA: "Stereoselective Drug Metabolism", Therapeutics and Pharmacokinetics in the 1990's,

Breckenridge, CO, March 1990 (Symposia presentation). 79. Kneer J, Blouin RA, Stoeckel K: "The Influence of Antacid and Ranitidine Administration on the

Pharmacokinetics of Oral Cefetamet Pivoxil", the 7th Mediterranean Congress of Chemotherapy, Barcelona, Spain, May 1990 (poster).

80. Chaudhary I, Parkinson A, Robertson LW, Blouin RA: "Phenobarbital Induction Defect in the Obese

Zucker Rat I", AAPS, Las Vegas, NV, November 1990 (poster). 81. Chaudhary I, Parkinson A, Robertson LW, Blouin RA: "Phenobarbital Induction Defect in the Obese

Zucker Rat II", AAPS, Las Vegas, NV, November 1990 (poster). 82. Chaudhary I, Nishihara, K, Robertson LW, Blouin RA: "Phenobarbital Induction Defect in the Obese

Zucker Rat III", AAPS, Las Vegas, NV, November 1990 (poster). 83. Chaudhary I, Nishihara K, Robertson LW, Blouin RA: "PCB Induction Defect in the Obese Zucker Rat",

AAPS, Las Vegas, NV, November 1990 (poster). 84. Hallak HO, Wedlund PJ, Foster TS, Blouin RA, John W, Patel IH: "Midazolam Disposition and

Response in Efficient and Poor Metabolizers of Dextromethorphan", ASCPT, San Antonio, TX, March 1991 (poster).

85. Blouin RA: "Phenobarbital in the Genetically Obese Zucker Rat: Differential Induction of Gene

Expression", Wayne State University, Detroit, MI, October 1990 (presentation). 86. Blouin RA, Bandyopadhyay AM, Chaudhary I: "Effect of Phenobarbital Treatment on Cytochrome P-

450IIC11 mRNA in Obese Zucker Rats", FASEB, Atlanta, GA, April 1991 (poster). 87. Bandyopadhyay AM, Chaudhary I, Blouin RA: "Molecular Mechanism of Phenobarbital Induction

Defect of Cytochrome P-450IIB1/IIB2 in Obese Zucker Rats", FASEB, Atlanta, GA, April 1991 (poster). 88. Chaudhary I, Tuntaterdtum S, Cibull ML, Blouin RA: "Effect of P-450 Inducers on Acetaminophen

Hepatotoxicity in Obese Zucker Rats", FASEB, Atlanta, GA, April 1991 (poster). 89. Chandler MHH, Hamelin BA, Clifton GD, Blouin RA, Wolf KM: "Terbutaline Pharmacodynamics in Young and

Elderly Asthmatics", ACCP, Minneapolis, MN, August 1991 (poster). 90. Chandler MHH, Hamelin BA, Blouin RA, Clifton GD, Wolf KM: "Responsiveness of Pure T-

Lymphocytes to a Beta-2 Agonist in Young and Elderly Asthmatics", ACCP, Minneapolis, MN, August 1991 (poster).

16

91. Blouin RA: "Central Issues Relevant to Clinical Pharmaceutical Scientist Training Programs", ACCP,

Minneapolis, MN, August 1991 (presentation). 92. Nishihara K, Chaudhary K, Cox S, Blouin RA: "Stereoselective Protein Binding of Flurbiprofen in Liver

and Renal Disease", AAPS, Washington, DC, November 1991 (poster). 93. Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, Wedlund PJ: "Effect of Age on Propranolol

Stereoselective Disposition in Man", AAPS, Washington, DC, November 1991 (poster). 94. Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, Wedlund PJ: "Effect of Age on Propranolol

Enantiomer Pharmacodynamics in Man", AAPS, Washington, DC, November 1991 (poster). 95. Blouin RA: "Management of Drugs in the Elderly", University of Cincinnati Medical Center

Geriatrics/Gerontology Speaking Series, Cincinnati, OH, October 1991 (presentation). 96. Blouin RA: "Stereoselective Drug Metabolism in the Elderly: Pharmacodynamic Considerations",

University of Cincinnati, College of Pharmacy, Cincinnati, OH, October 1991 (presentation). 97. Blouin RA: "Obtaining Peer Reviewed Funding: Critical Issues for Young Investigators”, ACCP Winter

Meeting, Phoenix, AZ, February 1992 (presentation). 98. Blouin RA: "Factors Influencing the Regulation and Expression of Hepatic Cytochrome P450 2B

Enzymes", 1992 AAPS Southeastern Regional Meeting, Wilmington, NC, April 1992 (Symposia presentation).

99. Bandyopadhyay A, Blouin RA: "Phenobarbital Induction Defect of Cytochrome P450 2B1/2B2 in Obese

Zucker Rat in Hepatocyte Culture", FASEB, Anaheim, CA, April 1992 (poster). 100. Toler SM, Young BA, Bandyopadhyay A, Blouin RA: "The Effect of Head Trauma on Hepatic

Cytochrome P-450 in the Fisher-344 Rat", AAPS 1992 Southeast Regional Meeting, Wilmington, NC, April 1992 (poster).

101. Zannikos PN, Bandyopadhyay A, Blouin RA: "Effect of Chronic High Fat Diet on the

Expression/Regulation of the Hepatic Cytochrome P-450 System", AAPS 1992 Southeast Regional Meeting, Wilmington, NC, April 1992 (poster).

102. Israel BC, Shedlofsky SI, Swim A, Blouin RA: "Decreased Theophylline and Antipyrine Clearance in

Cancer Patients Treated with Interferon-A (IFN)", ACCP, Toronto, Canada, August 1992 (poster). 103. Toler SM, Young BA, Bandyopadhyay A, Blouin RA: "The Effect of Head Trauma on Hepatic CYP3A

and CYP2C11 in the Fisher-344 Rat", 1992 Midwest Cytochrome P450 Symposium, Lafayette, IN, September 1992 (poster).

104. Zannikos PN, Bandyopadhyay A, Blouin RA: "Effect of Chronic High Fat Diet on the

Expression/Regulation of the Hepatic CYP2B1/2B2", 1992 Midwest Cytochrome P450 Symposium, Lafayette, IN, September 1992 (poster).

17

105. Blouin RA, Bandyopadhyay A, Chaudhary I, Robertson LW, Gemzick B, Parkinson A: "CYP2B Enzyme Induction Defect: Molecular Characterization”, 1992 Midwest Cytochrome P450 Symposium, Lafayette, IN, September 1992 (poster).

106. Israel BC, Shedlofsky SI, Swim A, Blouin RA: Effects of Endotoxin Induced Sepsis on Cytochrome P-

450 Drug Metabolism”, ACCP Annual Meeting, Reno, NV, August 1993 (presentation). 107. Blouin RA: "Stereoselective Drug Metabolism”, Fourth International Symposium on Chiral

Discrimination, Montreal, Quebec, September 1993 (Symposia presentation). 108. Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA: "CYP2B Enzyme Induction following

Treatment with 2,2’,4,4’,5,5’- Hexachlorobiphenyl in the obese Zucker rat”, AAPS, Orlando, FL, November 1993 (poster).

109. Nishihara KK, McNamara PJ, Blouin RA: "Expression of CYP2B Enzymes: Comparison of

Concentration-Response Relationships in Young & Adult Rats”, AAPS, Orlando, FL, November 1993 (poster).

110. Ma Li, Cohen DA, Blouin RA: "The Effect of Murine Acquired Immunodeficiency Syndrome (MAIDS)

on Hepatic Microsomal Steroid Hydroxylase Activities”, AAPS, Orlando, FL, November 1993 (poster). 111. Shedlofsky SI, Israel BC, Swim AT, Denison MG, Hill DB, McClain CJ, Blouin RA: "Decreased

Hepatic P450-Mediated Drug Clearances in Humans Given Endotoxin (LPS) as a Model of Gram-Negative Sepsis”, AASLD, Chicago, IL, November 1993 (poster).

112. Blouin RA: "Research in Clinical Sciences”, 11th Annual Merrillville Symposium on Pharmaceutical

Sciences Graduates Programs, Merrillville, IN, October 1993 (Symposia presentation). 113. Israel BC, Shedlofsky SI, Blouin RA: "Evaluation of an Animal Model of Sepsis: Effect on Hepatic

P450 Expression”, ACCP Annual Meeting, St. Louis, MO, August 1994 (poster). 114. Blouin RA: "Mechanism(s) of Phenobarbital Induction: Applications of a Mutant Rodent Model”,

University of Alberta, Edmonton, Alberta, April 1994 (presentation). 115. Roe AL, Howard G, Blouin RA: "The Effect of Acute and Chronic In Vivo Phenobarbital Treatment on

DNA Binding Proteins”, 10th International Symposium on Microsomes & Drug Oxidation, Toronto, Ontario, July 1994 (poster).

116. Young B, McClain CJ, Kindy M, Dempsey R, Blouin R, Gillespie M, Scheff S: "Pneumatic Impacter

Model of Head Injury Simulates Metabolic Aspects of Head Injury”, Congress of Neurosurgical Surgeons, Chicago, IL, October 1994.

117. Roe AL, Howard G, Blouin RA: "Acute and Chronic In Vivo Phenobarbital Treatment Effects on GRE

and AP-1 DNA Binding Proteins”, SOT 1995 Annual Meeting, Baltimore, MD, March 1995 (poster). 118. Boni J, Chaudhary I, Batastini G, Tonelli A, Woolcock I, DiStefano F, Vella A, Blouin R, Parkinson A,

Eldridge S, Davis H: "A Toxicokinetic and Mechanistic Toxicity Study of CL275,838 (A Novel Memory Enhancing Agent) after Subchronic Dosing in Rats”, AAPS, Miami, Fl, November 1995 (poster).

18

119. Rees WA, Chambers T, Fenger C, Harkins JD, Blouin RA, Holland R, Tobin T: "The Pharmacokinetics

and Bioavailability of Amantidine in the Horse: A Preliminary Report”, Am Assoc Equine Prac. 1995. 120. Blouin RA and Wedlund PJ: "Pharmacokinetics for the Pharmaceutical Scientist: A Short Course”, F.

Hoffmann LaRoche, Nutley, NJ, July 1995 (presentation). 121. Blouin RA: "Joint Pharm.D./Ph.D. Programs”, AACP Annual Meeting, Philadelphia, PA, July 1995

(presentation). 122. Israel BC, Shedlofsky SI, Tosheva R, Blouin RA: "Endotoxin Differentially Inhibits Hepatic

Cytochrome P450 Drug Metabolism in Female Volunteers”, ACCP Annual Meeting, Washington, DC, August 1995 (presentation).

123. Blouin RA: "Obese Zucker Rodent Model: Responsiveness to Phenobarbital Induction”, 1995 Midwest

Cytochromes P450 Symposium, Purdue University, West Lafayette, IN, September 1995 (presentation). 124. Roe AL, Howard G, Shedlofsky SI, Blouin RA: "Cytokine Regulation of CYP3A2 Expression in Rats

Treated with LPS”, SOT 1996 Annual Meeting, Anaheim, CA, March 1996 (poster). 125. Lu M, Blouin RA: "Evaluation of Formation Clearance of Dapsone Hydroxylamine as a Marker of

CYP3A Activity: An In Vivo and In Vitro Correlation”, AAPS 1996 Annual Meeting, Seattle, WA, October 1996 (presentation).

126. Blouin RA: "Obese Rodent Models: Alterations in Gene Expression of Drug Metabolizing Enzymes”,

1996 Annual Mini-Symposium in Nutritional Sciences, Lexington, KY, April 1996 (presentation). 127. Roe AL, Howard G, Shedlofsky S, Blouin RA: "The Effect of High Dose Endotoxin on Nuclear Protein

Binding: Implications on CYP3A2 Regulation”, 1996 Midwest Cytochromes P450 Symposium, Purdue University, West Lafayette, IN, September 1996 (poster).

128. Warren G, Roe AL, Hou J, Shedlofsky S, Blouin RA: "The Effect of High Dose Endotoxin on Hepatic

CYP3A2 Regulation”, 1996 Midwest Cytochromes P450 Symposium, Purdue University, West Lafayette, IN, September 1996 (poster).

129. Lu M, Blouin RA: "The Effect of Pregnenolone 16a-Carbonitrile on the Pharmacokinetics and

Metabolism of Dapsone”, 1996 Midwest Cytochromes P450 Symposium, Purdue University, West Lafayette, IN, September 1996 (poster).

130. Blouin RA: "The Effect of Head Trauma/Acute Phase Response on Brain and Liver Cytochrome P450

Enzymes”, The Second Annual Kentucky Spinal Cord and Brain Injury Trust Symposium 1996, Lexington, KY, June 1996 (presentation).

131. Lu M, Poloyac SM, Blouin RA: "Evaluation of Oxidation of Dapsone as a Marker of CYP3A Activity:

An In Vivo and In Vitro Correlation”, SOT 1997 Annual Meeting, Cincinnati, OH March 1997 (poster). 132. Warren G, Roe AL, Hou J, Shedlofsky S, Blouin RA: "The Effect of High Dose Endotoxin on CYP3A

Expression”, SOT 1997 Annual Meeting, Cincinnati, OH March 1997 (poster).

19

133. Roe AL, Howard G, Shedlofsky S, Blouin RA: "The Effect of High Dose Endotoxin on Nuclear Protein Binding: Implications on CYP3A2 Regulation”, SOT 1997 Annual Meeting, Cincinnati, OH, March 1997 (poster).

134. Blouin RA: "Special Pharmacokinetic Considerations in the Obese Patient”, APhA Annual Meeting, Los

Angeles, CA, March 1997 (Symposia presentation). 135. Watson A, Howard G, Shedlofsky S, Blouin RA: "Changes in Conjugation and Antioxidant Enzymes

following Endotoxin Exposure”, IUBMB, San Francisco, CA, August 1997 (poster). 136. Roe A, Howard G, Blouin RA: "Constitutive AP-1 Binding Activity in the Genetically Obese (fa/fa)

Zucker Rat”, IUBMB, San Francisco, CA, August 1997 (poster). 137. Roe A, Poloyac S, Howard G, Shedlofsky S, Blouin RA: "The Effect of High Dose Endotoxin on

Hepatic CYP2E1 Regulation and Expression”, IUBMB, San Francisco, CA, August 1997 (poster). 138. Rockich K, Hatton J, Kryscio R, Young B, Blouin RA: "The effect of Continuous Intravenous Infusion

of rhIGF-1 and Daily Subcutaneous Administration of rhGH on IGF-1 and IGFBP-3 Plasma Concentrations in Traumatic Brain Injured Patients”, AAPS, Boston, MA, November 1997 (poster).

139. Oakley GG, Roe AL, Blouin RA, Ganguly T, Vore M, Robertson W: "Activation of AP-1 and STAT

Transcription Factors by Non-Coplanar Polychlorinated Biphenyls”, SOT, Seattle, WA, March 1998 (poster).

140. Blouin RA: "Expression and Regulation of Xenobiotic-Metabolizing Enzymes in Obesity”, 12th

International Symposium on Microsomes and Drug Oxidations, Montpellier, France, July 1998 (Symposia presentation).

141. Blouin RA: "The Effect of Head Trauma/Acute Phase Response on Brain and Liver Cytochrome P450

Enzymes”, 4th Annual Kentucky Spinal Cord and Head Injury Research Symposium, Lexington, KY, July 1998 (presentation).

142. Rockich K, Blouin RA: "The Effect of the Acute Phase Response on Chlorzoxazone Pharmacokinetics

and CYP2E1 Activity in the Rat”, ACCP 1998 Annual Meeting, Cincinnati, OH, November 1998 (poster).

143. Blouin RA: "Relating In-Vitro Data to In-Vivo Drug Interactions”, ACCP 1998 Annual Meeting,

Cincinnati, OH, November 1998 (Symposia presentation). 144. Blouin RA: "Translational Research with Drug Interactions”, ACCP 1998 Annual Meeting, Cincinnati,

OH, November 1998 (Symposia presentation). 145. Warren G, Mattson M, Blouin RA: "Hepatic Cytochrome P450 Expression in IL-6 Knockout Mice

following Endotoxin Administration”, SOT 1999 Annual Meeting, New Orleans, LA, March 1999 (poster).

146. Roe AL, Warren G, Mattson M, Blouin RA: "AP-1 Binding Activity Is Altered in LPS-Treated TNF a

(p55/p75) Double Receptor Knockout Mice”, SOT 1999 Annual Meeting, New Orleans, LA, March 1999 (poster).

20

147. Gardner BM, Poloyac SM, Shedlofsky SI, Blouin RA: “Serum Protein Binding of Chlorzoxazone in

Human: The Effect of Endotoxin Administration”, ASHP 1998 Annual Meeting, Las Vegas, NV, December 1998 (poster).

148. Poloyac SM, Tosheva T, RT, Shedlofsky SI, Blouin RA: “Variable Changes in CYP2E1 Activity after

Endotoxin Administration in Humans”, SOT 1999 Annual Meeting, New Orleans, LA, March 1999 (poster).

149. Blouin RA: “Post-Graduate Education”, University of Minnesota Seminar Series, Minneapolis, MN,

March 1999 (Presentation). 150. Blouin RA: “Prediction Drug-Drug Interactions from In-Vitro Data”, University of Minnesota College

of Pharmacy Seminar Series, Minneapolis, MN, March 1999 (Presentation). 151. Van Ess PJ, Pedersen WA, Culmsee C, Mattson MP, Blouin RA: “Alterations in Cytochrome P450

Enzyme Activity in Transgenic Mice Expressing Familial Alzheimer’s Disease-Linked Mutant Beta Amyloid Precursor Protein”, AAPS 1999 Annual Meeting, New Orleans, LA, November 1999 (poster).

152. Poloyac SM, Blouin RA: “Tissues Specific Alterations in CYP2E1 Expression following Traumatic

Brain Injury in the Rat”, AAPS 1999 Annual Meeting, New Orleans, LA, November 1999 (poster). 153. Rockich KT, Tosheva T, RT, Shedlofsky SI, Blouin RA: “The Effect of Endotoxin Administration on

CYP3A4 Activity in Humans”, AAPS 1999 Annual Meeting, New Orleans, LA, November 1999 (poster).

154. Blouin RA, DiPiro JT, Evans WE, Fletcher CV, Johnson JA, Relling MV: “Establishing the Link:

Developing Proposals that Fill a Gap in Knowledge - Mock Study Section: Critique of Contemplated Methods”, 1999 ACCP Annual Meeting, Kansas City, MO, October 1999 (Symposia presentation).

155. Blouin RA: “Understanding Changes in Hepatic Drug Metabolism through Pharmacokinetic Data

Analysis of Model Probe Drugs”, 1999 Conference on Nonlinear Statistical Models: Implementation and Application, Lexington, KY, November 1999 (Symposia presentation).

156. Shedlofsky SI, Tosheva RT, Rockich KT, Cunningham CR, Goeger DE, Blouin RA: “Superiority of

Midazolam as a Probe for Assessing CYP3A4 Activity in Human Endotoxin Model”, SOT 2000 Annual Meeting, Nashville, TN, March 2000 (poster).

157. Blouin RA: “Expression and Regulation of Drug Metabolizing Enzymes in Obesity”, ASBMB/ASPET

Annual Meeting, Boston, MA, June 2000 (Symposia presentation). 158. Lubawy WC, Yokel RA, Blouin RA, Blumenschein K: “Advanced Degree Programs Integrated with the

Doctor of Pharmacy Curriculum as a Foundation for the Future”, AACP Annual Meeting, San Diego, CA, July 2000 (poster).

159. Van Ess PJ, Warren GW, Mattson MP, Blouin RA: “Effect of Clofibrate Administration on Cytochrome

P450 Activity in TNF p55/p75 Double Receptor Knockout Mice”, AAPS Annual Meeting, Indianapolis, IN, November 2000 (poster).

21

160. Van Ess PJ, Warren GW, Mattson MP, Blouin RA: “Enhanced Phenobarbital Induction of Hepatic CYP2B Parallels CAR Activation in Tumor Necrosis Receptor Double Knockout Mice”, AAPS Annual Meeting, Denver, CO, November 2001 (poster).

161. Blouin RA (panel member): “Promoting German, Austrian, and Swiss Investment in Kentucky”,

Kentucky German Business Council 2nd Annual Conference, Lexington, KY October 2001. 162. Van Ess PJ, Warren GW, Mattson MP, Blouin RA: “Effect of Phenobarbital on Cytochrome P450

Induction in Tumor Necrosis Factor and Interleukin-6 Defficient Mice”, 33rd Annual Pharmaceutical Graduate Student Research Meeting, Madison, WI, July 2001 (Dr. Van Ess received 2nd place poster presentation award for this work).

163. Tosheva RT, Van Ess P, Cunningham CR, Blouin RA, Shedlofsky SI: “Increased CYP2E1 Activity and

Enhanced Systemic Oxidative Stress after Endotoxin in Humans”, SOT Annual Meeting, Nashville, TN, March 2002.

164. Van Ess P, Charriez C, Tosheva RT, Shedlofsky SI, Blouin RA: “Correlation between NFkB and

Changes in Chlorzoxazone Disposition following an Acute Phase Response”, 2002 ACCP Spring Practice and Research Forum, Savannah, GA, April 2002 (poster).

165. Blouin RA: “The Impact of Obesity on Drug Pharmacokinetics and Pharmacodynamics”, 2002 ACCP

Spring Practice and Research Forum, Savannah, GA, April 2002 (presentation). 166. Blouin RA: “The Effect of the Acute Phase Response on CYP2E1 Expression and Regulation”,

Department of Medicinal Chemistry Seminar Series, The Ohio State University, Columbus, OH, April 2002 (presentation).

167. Blouin RA: “Effect of Obesity on Drug Metabolism”, University of Kentucky Center for Nutritional

Sciences Seminar Series, Lexington, KY April 2002 (presentation). 168. Blouin, RA: “Future of Research and Graduate Education in Clinical Pharmacy”, University of Illinois at

Chicago, Chicago, Illinois July 2005 (presentation). 169. Blouin, RA: “Moving Learning up Bloom’s Taxonomy”, 2007 AACP Interim Meeting, Arlington, VA,

February 2007 (presentation). 170. Blouin, RA: The 11th Annual Michael J Ordman Memorial Lecture, Massachusetts College of Pharmacy

and Health Sciences, Boston, MA, March 2007 (presentation). 171. Blouin, RA: “Moving up Bloom’s Taxonomy”, University of Maryland Faculty Assembly, Baltimore,

MD, April 2007 (presentation). 172. Blouin, RA: “Educational Renaissance”, University of Minneapolis Faculty Retreat, Minneapolis, MN,

May 2007 (presentation). 173. Blouin, RA: “Educational Renaissance at the University of North Carolina”, ASHP Annual Midyear

Clinical Meeting, Las Vegas, NV, December 2007 (round table discussion).

22

174. Joyner, P, Pollack, GM, Blouin, RA: “Educating the Next Generation of Pharmacy Students: An Educational Renaissance at the UNC School of Pharmacy”, 2008 AACP Interim Meeting, Arlington, VA, February 2008 (round table discussion).

175. Blouin, RA: “Educating the Next Generation of Learners”, University of West Virginia Faculty Retreat,

Morgantown, WV, January 2008 (presentation). 176. Blouin, RA: “Educational Renaissance: Experience at the University of North Carolina”, University of

Wisconsin, Madison WI, February 2008 (presentation). 177. Blouin RA: “The Role of Research in a Professional Curriculum”, US-Thai Pharmacy Consortium: For

the Development of Pharmacy Education in Thailand, Madison WI, July 2008 (presentation). 178. Blouin RA, Joyner P, Persky A, Pollack GM: “Educating the Next Generation of Pharmacy Students: An

Educational Renaissance at the UNC Eshelman School of Pharmacy”, 2008 AACP Annual Meeting, Chicago IL, July 2008 (presentation).

179. Blouin RA: “2009 First Tennessee Chair of Excellence Distinguished Visiting Professor: Translational

Research and Training Opportunities and Challenges”, University of Tennessee School of Pharmacy, Memphis TN, January 2009 (presentation).

180. Blouin RA: “2009 Rho Chi Lecturer: Educational Renaissance and the Next Generation of Learners”,

University of Kentucky College of Pharmacy, Lexington KY, March 2009 (presentation). 181. Blouin RA: “2009 Rho Chi Lecturer: A Call to Leadership”, University of Kentucky College of

Pharmacy, Lexington KY, March 2009 (presentation). 182. Blouin RA: “Strategies to Focus and Enhance Research Funding”, University of Houston College of

Pharmacy, League City TX, May 2009 (presentation). 183. Blouin RA: “Clinical Pharmaceutical Scientists PhD Program: Success and Lessons Learned”, University

of Southern California School of Pharmacy, Los Angeles CA, July 2009 (presentation). 184. Blouin RA, Speedie M, Jordan R: “Sharing the Dynamics of Transforming Gifts”, 2009 AACP Annual

Meeting, Boston MA, July 2009 (panel). 185. Blouin RA: “Roles of Innovation in Education Delivery”, 2009 AACP Curricular Change Summit,

Scottsdale AZ, September 2009 (symposia presentation). 186. Blouin RA: “Educating the Next Generation of Learners: A Case for Change”, University of British

Columbia, Vancouver BC, November 2009 (presentation). 187. Blouin RA: “Educational Renaissance: A Case for Change”, North Carolina Research and Education

Network (NCREN) Community Celebration 2009, Cary NC, December 2009 (symposia presentations). 188. Blouin RA: “Preparing a Renaissance in Pharmacy Education: A Hybrid Delivery Model”,

EduPharm@Asia 2010 Symposium, National University of Singapore, Singapore, April 2010 (symposia presentation).

23

189. Blouin RA: “Roles of Innovation in Education Delivery”, Wayne State University, Detroit MI, May 2010 (presentation).

190. Blouin RA: “Patient Centered Care: Educating the Next Generation of Pharmacists”, 67th AFPC

Conference, Richmond BC, Canada, June 2-5, 2010 (symposia presentation). 191. Blouin RA, Ratka A, Zgarrick DP: “Graduate Student Program: How to Get Your First Job”, 2010 AACP

Annual Meeting, Seattle WA, July 2010 (panel). 192. Van Amburgh JA, Surratt CK, Green JA, Gallucci RM, Colbert J, Zatopek SL, Blouin RA: “Succession

Planning in US Pharmacy Schools”, 2010 AACP Annual Meeting, Seattle WA, July 2010 (poster). 193. Duncan W, Medina MS, Fielding DW, Brazeau GA, Austin ZH, Blouin RA, Meyer SM: “Speaking the

Same Tongue: Coming to Consensus on the Language of Assessment and Evaluation”, 2010 AACP Annual Meeting, Seattle WA, July 2010 (presentation).

194. Duncan W, Medina MS, Fielding DW, Brazeau GA, Austin ZH, Blouin RA, Meyer SM: “Charting the

Course: Planning Efficient and Effective Approaches to Assessment and Evaluation”, 2010 AACP Annual Meeting, Seattle WA, July 2010 (presentation).

195. Blouin RA: “Educating the Next Generation of Learners”, 2010 NABP/AACP District III Meeting,

Blowing Rock NC, August 2010 (presentation). 196. Blouin RA: “Integration of the Education and Research Missions: Optimizing Impact at a Research

Intensive University”, Inaugural 2010 Arthur D. Bloom College of Pharmacy Seminar Series, University of Utah, College of Pharmacy, Salt Lake City Utah, October 2010 (presentation).

197. Blouin RA: “Education Reform in Higher Education: A Need for Change”, University of Montana,

Missoula MT, January 2011 (presentation). 198. Blouin RA: “Curriculum Revision: Effects on Research and Teaching Missions of Departments”,

Associate of Medical Pharmacology Chairs, Cancun, Mexico, January 2011 (presentation). 199. Blouin RA: “Good to Great: A UNC Eshelman School of Pharmacy Case Study”, Faculty Learning

Community on Strategy and Leadership, The University of North Carolina at Chapel Hill, Chapel Hill NC, February 2011 (presentation).

200. Blouin RA: “Transformative Leadership and Teams”, Transformational Leadership: Deans and Chairs as

Agents of Change - 2011 AACP Interim Meeting, (panel discussion with Lyle Bootman, Stephen Schondelmeyer, Kathleen Johnson), Seattle WA, February 2011 (panel discussion).

201. Blouin RA: “From the Asheville Project to Health Care Reform: The Value Added Proposition of a

Pharmacist”, William E. Hassan Jr. Distinguished Rho Chi Memorial Lecture, Massachusetts College of Pharmacy & Health Sciences-Boston, Boston MA, March 2011 (presentation).

202. Blouin RA: “A Call to Leadership: A Personal Journey”, The Rho Chi Psi Chapter of the Massachusetts

College of Pharmacy & Health Sciences Keynote Speaker, Boston MA, March 2011 (presentation).

24

203. Blouin RA: “Active Learning and Leveraging Technology in the Classroom”, University of Illinois College of Pharmacy Faculty Retreat, Lake Geneva WI, May 2011 (presentation).

204. Blouin RA: “Global Pharmacy Education and Colleges of Pharmacy: Challenges and Opportunities –

Transforming Pharmacy in Singapore: A Partnership”, 2011 AACP Annual Meeting, San Antonio TX, July 2011 (presentation).

205. Blouin RA: “Developing and Evaluating Faculty Excellence”, University of Texas at Austin, College of

Pharmacy Faculty Retreat, Austin TX, August 2011 (presentation). 206. Blouin RA: “Integration of the Education and Research Missions: Optimizing Impact at a Research

Public University”, Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, November 2011 (presentation).

207. Blouin RA: “Education Reform in Higher Education: A Need for Change”, Bill Gatton College of

Pharmacy, East Tennessee State University, Johnson City, TN, November 2011 (presentation). 208. Blouin RA: “Our Research Mission: Scope, Focus, and Collaborations”, Tokushima University,

Tokushima, Japan, January 2012 (symposia presentation). 209. Blouin RA: “Integration of the Education and Research Mission: Optimizing Impact at a Research

Intensive University”, The Ohio State University, Columbus, OH, April 5, 2012 (presentation). 210. Blouin RA: “2012 Rho Chi Lecturer: Changing the World – One Student at a Time”, The Ohio State

University, Columbus, OH, April 5, 2012 (presentation). 211. Blouin RA: “Reimaging the Public University of the 21st Century: UNC Library Strategic Planning

Retreat”, University of North Carolina at Chapel Hill, Chapel Hill, NC, June 2012 (reactor panel member).

212. Blouin RA: “Transformation of a School of Pharmacy through Strategic Planning”, University of New

Mexico, Albuquerque, NM, January 2013 (presentation). 213. Blouin RA: “Cultivating the Science and Scientists for the 21st Century Drug Discovery and

Development”, 2013 AAAS Annual Meeting, Boston, MA, February 2013 (presentation). 214. Blouin RA: “Integration of the Education and Research Missions: Optimizing Impact in Health Science

Professions”, Krantz Lecturer at the University of the Sciences, Philadelphia, PA, April 2013 (presentation).

215. Blouin RA: “Creating a Culture to Support Research and Scholarship”, Wayne State University, Detroit,

MI, June 2013 (presentation). 216. McClurg MR, Singleton S, Rodgers PT, Lee C, McLaughlin, Moore J, Guidotti M, Joyner PU, Mumper

R, Blouin RA: “A Systems Approach to Transformation in Pharmacy Education”, 2013 AACP Annual Meeting, Chicago, Il, July 2013 (poster).

217. Blouin RA, Tracy T, Mumper R, Chrisman L: “Deans Networking Session: Effective Utilization of

Administrative Tools”, AACP Annual Meeting, Chicago, Il, July 2013 (networking session).

25

218. Blouin RA, Van Amburgh JA, Keefe K: “Leadership Programming: Succession Planning in Academic

Pharmacy”, AACP Annual Meeting, Dallas, TX, July 2014 (presentation). 219. Blouin RA, McClurg M, Joyner PU: “The Life Cycle of a Strategic Plan: Environmental Scan to

Assessment”, AACP Annual Meeting, Dallas, TX, July 2014 (presentation). 220. Blouin RA, McClurg M, Easter J, Trygstad T: “Teams Leading Change: Glaxo Smith Kline, Community

Care of North Carolina, and the UNC Eshelman School of Pharmacy”, AACP Interim Meeting, Austin, TX February 2015 (presentation).

221. Blouin RA: “The Layered Learner Practice Model” AACP Interim Meeting, Austin, TX February 2015

(presentation). 222. Allen DD, Blouin RA, McKay: “Building a Functional, Productive and Successful Research Program at

College and Department Level”, AACP Annual Meeting, National Harbor, MD, July 2015 (panel presentation).

223. Blouin RA: “Engaging University Administration Effectively to Advance your School or College”,

AACP Annual Meeting, National Harbor, MD, July 2015 (presentation). 224. Blouin RA: “Decision Making in Practice, the Integration of Science, The Dean’s Role”, FIP 6th

Academic Institutional Membership Forum, Dusseldorf, Germany, September 2015. RESEARCH AND CREATIVE PRODUCTIVITY PUBLICATIONS: 1. Westerfield BT, Blouin RA: Ethchlorvynol intoxication. South Med J. 70:1019-1020, 1977. 2. Bivens BA, Rapp RP, Griffen WO Jr., Blouin RA, Bustrack JA: Dopamine - phenytoin interaction.

Arch Surg 113:245-249, 1978. 3. Rapp RP, Bustrack JA, Blouin RA: Dopamine interaction. Drug Intell Clin Pharm 12:249, 1978. 3. Blouin RA, Mann HJ, Griffen WO Jr., Bauer LA, Record KE: Tobramycin pharmacokinetics in

morbidly obese patients. Clin Pharmacol Ther 26:508-512, 1979. 5. Bauer LA, Blouin RA, Griffen WO Jr., Record KE, Bell RM: Amikacin pharmacokinetics in morbidly

obese patients. Am J Hosp Pharm 37:519-522, 1980. 6. Blouin RA, Bauer LA, Piecoro JJ, Holland NH: Decreased gentamicin half-life during peritoneal

dialysis: A case report. Drug Intell Clin Pharm 14:218-219, 1980. 7. Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivens BA: Theophylline hemodialysis clearance.

Ther Drug Monit 2:221-223, 1980.

26

8. Blouin RA, Elgert JF, Bauer LA: Theophylline clearance: effect of marked obesity. Clin Pharmacol Ther 28:619-623, 1980.

9. Blouin RA, Erwin WG, Dutro MP, Bustrack JA, Rowse KL: Chloramphenicol hemodialysis clearance.

Ther Drug Monitor 2:351-354, 1980. 10. Oeltgen PR, Hamann SR, Blouin RA: Comparison of gentamicin assays. Ther Drug Monit 2:423-425,

1980. 11. Bauer LA, Blouin RA: Influence of age on theophylline clearance in patients with chronic obstructive

pulmonary disease. Clin Pharmacokinet 6:469-474, 1981. 12. Dionne RE, Bauer LA, Gibson GA, Griffen WO Jr., Blouin RA: Estimating creatinine clearance in

morbidly obese patients. Am J Hosp Pharm 38:841-844, 1981. 13. Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB: Phenytoin-dexamethazone interaction: a

previously unreported observation. Surg Neurol 16:23-24, 1981. 14. Bailey RT, Young AB, Rapp RP, Blouin RA: Theophylline toxicity after the use of aminophylline in the

treatment of cerebral vasospasm. Neurosurgery 9:722-724, 1981. 15. Bauer LA, Blouin RA: Influence of age on tobramycin pharmacokinetics in patients with normal renal

function. Antimicrob Agents Chemother 20:587-589, 1981. 16. Bauer LA, Bauer SP, Blouin RA: The effect of acute and chronic renal failure on theophylline clearance.

J Clin Pharmacol 22:65-68, 1982. 17. Lawson LA, Blouin RA, Parker PF: Quality assurance program for a clinical pharmacokinetic service.

Am J Hosp Pharm 39:607-609, 1982. 18. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr.,: Vancomycin pharmacokinetics in

normal and morbidly obese subjects. Antimicrob Agents Chemother 21:575-580, 1982. 19. Blouin RA, Erwin WG, Foster TS, Scott S: Pharmacokinetics of theophylline in young and elderly

subjects. Gerontology 28:323-327, 1982. 20. Hamann SR, Oeltgen PR, Shank WA, Blouin RA, Natarajan L: Evaluation of gentamicin

pharmacokinetics during peritoneal dialysis. Ther Drug Monitor 4:297-300, 1982. 21. Bauer LA, Blouin RA: Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 31:301-304,

1982. 22. Bauer LA, Blouin RA: Gentamicin pharmacokinetics: Effect of aging in patients with normal renal

function. J Am Geriatr Soc 30:309-311, 1982. 23. Bauer LA, Blouin RA: Amikacin pharmacokinetics in young men with pneumonia. Clin Pharm 1:353-

355, 1982.

27

24. Bauer LA, Piecoro JJ, Wilson HD, Blouin RA: Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis. Clin Pharm 2:262-264, 1983.

25. Bauer LA, Blouin RA: Influence of age on amikacin pharmacokinetics in patients without renal disease:

Comparison with gentamicin and tobramycin. Eur J Clin Pharmacol 24:639-642, 1983. 26. Benedek IH, Fiske WD, Griffen WO Jr., Bell RM, ,Blouin RA, McNamara PJ: Serum alpha-1 acid

glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol 16:751-754, 1983. 27. Bauer LA, Blouin RA: Phenytoin Michaelis-Menton pharmacokinetics in Caucasian paediatric patients.

Clin Pharmacokinet 8:545-549, 1983. 28. Hamann SR, Blouin RA, McAllister RG: Clinical pharmacokinetics of verapamil. Clin Pharmacokinet

9:26-41, 1984. 29. Benedek IH, Blouin RA, McNamara PJ: Influence of smoking on serum protein composition and the

protein binding of drugs. J Pharm Pharmacol 36:214-216, 1984. 30. Bauer LA, Edwards WA, Randolph FP, Blouin RA: Cimetidine induced decreases in lidocaine

metabolism. Am Heart J 108:413-415, 1984. 31. Oeltgen PR, Shank WA, Blouin RA, Clark T: Clinical evaluation of the Abbott TDx(TM) fluorescence

polarization immunoassay analyzer. Ther Drug Monit 6:360-367, 1984. 32. O'Neal W, Whitten KM, Baumann RJ, Blouin RA, Piecoro JJ: Lack of serious toxicity following

carbamazepine overdose. Clin Pharm 3:545-547, 1984. 33. Brouwer KL, Kostenbauder HB, McNamara PJ, Blouin RA: Phenobarbital in the genetically obese

Zucker rat. I. Pharmacokinetics after acute and chronic administration. J Pharmacol Exp Ther 231:649-653, 1984.

34. Brouwer KL, Kostenbauder HB, McNamara PJ, Blouin RB: Phenobarbital in the genetically obese

Zucker rat. II. In Vivo and In Vitro assessments of microsomal enzyme induction. J Pharmacol Exp Ther 231:654-659, 1984.

35. Benedek IH, Blouin RA, McNamara PJ: Serum protein binding and the role of increased alpha 1-acid

glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 18:941-946, 1984. 36. Hamann SR, Blouin RA, Chang SL, Kaltenborn KE, Tan TG, McAllister RG: Effects of hemodynamic

changes on the elimination kinetics of verapamil and nifedipine. J Pharmacol Exp Ther 231:301-305, 1984.

37. Blouin RA, Brouwer KL, Record KE, Griffen WO Jr., Plezia PM, John W: Amikacin pharmacokinetics

in morbidly obese patients undergoing gastric by-pass surgery. Clin Pharm 4:70-72, 1985. 38. Hamann SR, Tan TG, Kaltenborn KE, Brouwer KLR, Blouin RA, Chang SL, Vore M, McAllister RG:

Effects of phenobarbital and SKF-525A on In Vitro hepatic metabolism of verapamil and nifedipine. Pharmacology 30:121-128, 1985.

28

39. Oeltgen PR, Blouin RA, Spurrier WA, Myers RD: Hibernation "Trigger" alters renal function in the primate. Physiol Behav 34:79-81, 1985.

40. McAllister RG, Hamann SR, Blouin RA: Pharmacokinetics of calcium entry blockers. Am J Cardiol

55:30B-40B, 1985. 41. Gibson GA, Blouin RA, Bauer LA, Rapp RP, Tibbs PA: Influence of high dose pentobarbital on

theophylline pharmacokinetics: a case report. Ther Drug Monitor 7:181-184, 1985. 42. Benedek IH, Blouin RA, McNamara PJ: Altered drug-serum protein binding in the genetically obese

Zucker rat. J Pharm Sci 74:837-840, 1985. 43. Wermeling D, Record K, Bell R, Porter W, Blouin RA: Hemodialysis clearance of pentobarbital during

continuous infusion: A case report. Ther Drug Monit 7:485-487, 1985. 44. Michael KA, Mohler JL, Blouin RA, Lucas BA, Rapp RP: Failure of creatinine clearance to predict

gentamicin half-life in a renal transplant patient with diabetes mellitus. Clin Pharm 4:572-575, 1985. 45. Mohler JL, Barton SD, Blouin RA, Cowen DL, Flanigan RC: The evaluation of creatinine clearance in

spinal cord injured patients. J Urology 136:366-369, 1986. 46. Fiske WD, Blouin RA, Mitchell B, McNamara PJ: Renal function in the obese Zucker rat. Int J Obes

10:175-183, 1986. 47. Wermeling DP, Blouin RA, Porter WH, Rapp RP, Tibbs PA: Pentobarbital pharmacokinetics in patients

with severe head injury. Drug Intell Clin Pharm 21:459-463, 1987. 48. Huang Chandler MH, Guttendorf RJ, Blouin RA, Wedlund PJ: Simultaneous quantitation of d- and l-

hexobarbital in rat blood by HPLC. J Chromatogr 419: 426-432, 1987. 49. Blouin RA, Kolpek JH, Mann HJ: Influence of obesity on drug disposition. Clin Pharm 6:706-714,

1987. 50. Blouin RA, Dickson P, McNamara PJ, Cibull M, McClain C: Phenobarbital induction and

acetaminophen hepatotoxicity: resistance in the obese Zucker rodent. J Pharmacol Exp Ther 243:565-570, 1987.

51. Clifton GD, Blouin RA, Dilea C, Schran HF, Hassell AE, Gonasun LM, Foster TS: The

pharmacokinetics of oral isradipine in normal volunteers. J Clin Pharmacol 28:36-42, 1988. 52. Chandler MH, Scott SR, Blouin RA: Age-associated stereoselective alterations in hexobarbital

metabolism. Clin Pharmacol Ther 43:436-441, 1988. 53. McNamara PJ, Blouin RA, Brazzell RK: The protein binding of phenytoin, propranolol, diazepam and

AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum. Pharm Res 5:261-265, 1988. 54. McNamara PJ, Blouin RA, Brazzell RK: Serum protein binding of AL01576, a new aldose reductase

inhibitor. Pharm Res 5:319-321, 1988.

29

55. Chandler MH, Blouin RA: Theophylline pharmacokinetics in the aged: A review. J Geriatric Drug Ther 3:23-40, 1988.

56. Chandler MH, Schran HF, Cutler RE, Smith AJ, Gonasun LM, Blouin RA: The effects of renal function

on the disposition of isradipine. J Clin Pharmacol 28:1076-1080, 1988. 57. Heintz RC, Ducarre JM, Blouin RA, Guengi A: Influence of oral dose escalation on the

pharmacokinetics of tenoxicam [Tilcotil] in healthy male subjects. Eur J Rheum Inflam 9-15, 1988. 58. Colangelo P, Chandler M, Blouin R, McNamara P: Stereoselective binding of propranolol. Br J Clin

Pharmacol 27:519-522, 1989. 59. Blouin RA, Kneer J, Stoeckel K: Pharmacokinetics of cefetamet (RO15-8074) and oral sefetamet pivoxil

(RO15-8075) in young and elderly subjects. Antimicrob Ag Chemoth 33:291-296, 1989. 60. Foster TS, Kielar RA, Blouin RA, Parr MD, Barton S, Perchak GJ, Johnson JB: Maintenance of

previously controlled intraocular pressure in patients with glaucoma or ocular hypertension: Comparison of four regimens of methazolamide. Glaucoma 11:67-71, 1989.

61. Blouin RA, Clifton GD, Adams MA, Foster TS, Flueck J: Biopharmaceutical comparison of two

levothyroxine sodium products. Clin Pharm 8:588-592, 1989. 62. Kneer J, Tam YK, Blouin RA, Frey FJ, Keller E, Stathakis C, Luginbuehl B, Stoeckel K:

Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency. Antimicrob Agents Chemother 33:1952-1957, 1989.

63. Hatton J. Parr MD, Blouin RA: Estimation of creatinine clearance in patients with Cushing's Syndrome.

Drug Intell Clin Pharm 23:974-976, 1989. 64. Guttendorf RJ, Britto M, Blouin RA, Foster TS, John W, Pittman KA, Wedlund PJ: Rapid screening for

polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol 29:373-380, 1990.

65. McNamara PJ, Blouin RA: Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in

the obese Zucker rats. J Pharm Sci 79:301-304, 1990. 66. Chandler MH, Clifton GD, Burki NK, Hunt BA, Blouin RA: Pulmonary function in the elderly: response

to theophylline bronchodilation. J Clin Pharmacol 30:330-335, 1990. 67. Hayton WL, Kneer J, Blouin RA, Stoeckel K: Pharmacokinetics of intravenous cefetamet and oral

cefetamet pivoxil in patients with hepatic cirrhosis. Antimicrob Agents Chemoth 34:1318-1322, 1990. 68. Schoerlin MP, Blouin RA, Pfefen JP, Guentert TW: Comparison of the pharmacokinetics of

moclobemide in poor and extensive metabolizers of debrisoquine. Acta Psychiatr Scand Suppl 360:98-100, 1990.

69. Blouin RA, Kneer J, Ambrose RJ, Stoeckel K: Influence of antacid and ranitidine on the

pharmacokinetics of oral cefetamet pivoxil. Antimicrob Agents Chemoth 34:1744-1748, 1990.

30

70. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ: Limitation to the use of the urinary S/R mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 31:350-352, 1991.

71. Colangelo P, Rapp R, Blouin R and Kenady D: Comparative bioavailability and safety of two parenteral

vancomycin formulations. J N Dev Clin Med 8:11-20, 1991. 72. Blouin RA, Cloyd JC, Ludden TM, Kroboth PD: Central issues relevant to clinical pharmaceutical

scientist training programs. Pharmacotherapy 11:257-263, 1991. 73. Smith DA, Chandler MH, Shedlofsky SI, Wedlund PJ, Blouin RA: Age-dependent stereoselective

increase in the oral clearance of hexobarbitone isomers caused by rifampin. Br J Clin Pharmacol 32:735-39, 1991.

74. Blouin RA, Hamelin BA, Smith DA, Foster TS, John WJ, Welker HA: Fleroxacin pharmacokinetics in

patients with liver cirrhosis. Antimicrob Ag Chemoth 36:632-638, 1992. 75. Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, Demaria AN, Wedlund PJ: Age and

propranolol stereoselective disposition in humans. Clin Pharmacol Ther 51:489-494, 1992. 76. Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, Demaria AN, Wedlund PJ: Age and beta-

adrenergic receptor sensitivity to S(-)- and R,S(+/-)-propranolol in humans. Clin Pharmacol Ther 51:549-554, 1992.

77. Hamelin BA, Blouin RA, Wolf KM, Clifton GD, Chandler MH: In vivo and in vitro beta-2 adrenergic

receptor responsiveness in young and elderly asthmatics. Pharmacotherapy 12:376-382, 1992. 78. Blouin RA, Chaudhary I, Nishihara K, Cox SA: The effect of liver and renal disease on stereoselective

serum binding of flurbiprofen. Br J Clin Pharmacol 35:62-64, 1993. 79. Blouin RA: Issues in pharmacotherapy: Hepatic cytochrome P450 - Application of animal models to

therapeutic problems in humans. The ACCP Report 13:(2),1993. 80. Israel BC, Blouin RA, McIntyre W, Shedlofsky SI: Effects of interferon-alpha monotherapy on hepatic

drug metabolism in cancer patients. Br J Clin Pharmacol 36:229-235, 1993. 81. Blouin RA, Bandyopadhyay AM, Chaudhary I, Robertson LW, Gemzik B, Parkinson A: Cytochrome

P450 2B enzyme (CYP2B) induction defect following phenobarbital treatment in the fa/fa rat: Molecular characterization. Arch Biochem Biophys 303:313-320, 1993.

82. Chaudhary I, Tuntaterdtum S, McNamara PJ, Robertson LW, Blouin RA: Effect of genetic obesity and

phenobarbital treatment on the hepatic conjugation pathways. J. Pharmacol. Exp. Ther 265:1333-1338, 1993.

83. Blouin RA, Stoeckel K: Cefetamet pivoxil clinical pharmacokinetics. Clin.Pharmacokinet 25:172-188,

1993. 84. Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA: Effect of nutritional obesity on the

induction of CYP2B enzymes following phenobarbital treatment. Drug Metab Dispos 21:782-787, 1993

31

85. Toler SM, Young B, McClain CJ, Shedlofsky SI, Bandyopadhyay AM, Blouin RA: Head injury and cytochrome P-450 enzymes. Differential effects on mRNA and protein expression in the Fischer-344 rats. Drug Metab Dispos 21:1064-1069, 1993.

86. Bandyopadhyay AM, Chaudhary I, Robertson LW, Gemzik B, Parkinson A, Blouin RA: Expression of a

male-specific cytochrome P450 isozyme (CYP2C11) in fa/fa Zucker rats: effect of phenobarbital treatment. Arch Biochem Biophys 307:386-390, 1993.

87. Tuntaterdtum S, Chaudhary I, Cibull ML, Robertson LA, Blouin RA: Acetaminophen hepatotoxicity:

influence of phenobarbital and ß-naphthoflavone treatment in obese and lean Zucker rats. Toxicol Appl Pharmacol 123:219-225, 1993.

88. Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA: Expression of the CYP3A and

CYP2C11 enzymes in a nutritionally obese rodent model: response to phenobarbital treatment. Int J Obes Relat Metab Disord 18:369-374, 1994.

89. Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA: Cytochrome P450 2B enzyme induction

defect after 2,2’,4,4’,5,5’-hexachlorobiphenyl treatment in the fa/fa Zucker rat. J Pharmacol Exp Ther 268:1565-1570, 1994.

90. Blouin RA, McNamara PJ, Chandler MHH, Kostenbauder HB: Development of a clinical pharmacology

program at the University of Kentucky College of Pharmacy. Am J Pharm Educ 58:289-293, 1994. 91. Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA: Endotoxin administration to humans

inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 94:2209-2214, 1994. 92. Chen S, Chou W, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR,

Wedlund PJ: The cytochrome P450-2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60:522-534, 1996.

93. Roe AL, Blouin RA, Howard G: In vivo phenobarbital treatment increases protein binding to a putitive

AP-1 site in the CYP2B2 promoter. Biochem Biophys Res Commun 228:110-114, 1996. 94. Shedlofsky SI, Israel BC, Tosheva R, Blouin RA: Endotoxin depresses hepatic cytochrome P450-

mediated drug metabolism in women. Br J Clin Pharmacol 43:627-632, 1997. 95. Rees WA, Harkins JD, Woods WE, Blouin RA, Lu M, Fenger C, Holland RE, Chambers TM, Tobin T:

Amantadine and equine influenza: Pharmacology, pharmacokinetics, and neurological effects in the horse. Equine Vet J 29(2):104-110, 1997.

96. Roe AL, Howard G, Hou G, Howard G, Shedlofsky S, Blouin RA: The effect of high dose endotoxin on

CYP3A2 expression in the rat. Pharm Res 15:1603-1608, 1998. 97. Stoeckel K, Hofheinz W, Laneury JP, Duchene P, Shedlofsky SI, Blouin RA: Stability of cephalosporin

prodrug esters in human intestinal juice: Implications for oral bioavailability. Antimicrob Agents Chemother 42:2602-2606, 1998.

98. Roe AL, Howard G, Blouin RA: Characterization of nuclear protein binding (AP-1, GR, and STAT) in

the genetically obese (fa/fa) Zucker rat. Life Sci 63:1339-1346, 1998.

32

99. Blouin RA, Warren GW: Pharmacokinetic considerations in obesity. J. Pharm. Sci 88:1-7, 1999. 100. Roe AL, Howard G, Blouin RA, Snawder JE: Characterization of cytochrome P450 and glutatione S-

transferase activity and expression in male and female ob/ob mice. Int. J. Obesity 23:48-53, 1999. 101. Watson AM, Warren G, Howard G, Shedlofsky SI, Blouin RA: Activities of conjugating and antioxidant

enzymes following endotoxin exposure. J Biochem Mol Toxicol 13:63-69, 1999. 102. Warren GW, Poloyac SM, Gary DS, Mattson MP, Blouin RA: Hepatic cytochrome P-450 expression in

the tumor necrosis factor-alpha rceptor (p55/p75) knockout mice after endotoxin administration. J Pharmacol Exp Ther 288:945-950, 1999.

103. Blouin RA, Farrell GC, Ioannides C, Renton K, Watlington CO: Impact of diseases on detoxification. J

Biochem Mol Toxicol 13:215-218, 1999. 104. Watson AM, Poloyac SM, Howard G, Blouin RA: The effect of leptin on cytochrome P-450,

conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metab Dispos 27 (6):695-700, 1999. 105. Lu M, Poloyac SM, McNamara PJ, Blouin RA: The effect of pregnenolone 16 alpha-carbonitrile on the

pharmacokinetics and metabolism of dapsone in rats. J Pharm & Pharmacol 51:803-810, 1999. 106. Rockich K, Blouin RA: The effect of the acute phase response on the pharmacokinetics of

chlorzoxazone and cytochrome P450 2E1 in vitro activity in rats. Drug Metab Dispos 27:1074-1077, 1999.

107. Rockich K, Hatton J, Kryscio D, Young B, Blouin RA: Effect of intravenous infusion of rhIGF-1 and

daily subcutaneous rhGH and IGFBP-3 levels in brain injury. Pharmacotherapy 19:1432-1436, 1999. 108. Poloyac SM, Tosheva RT, Shedlofsky SI, Blouin RA: The effect of endotoxin administration on the

pharmacokinetics of chlorzoxazone in humans. Clin Pharmacol Ther 66:554-562, 1999 109. Poloyac SM, Perez-Rivera AA, Scheff S, Blouin RA: Tissue specific alterations in the 6-hydroxylation

of chlorzoxazone following traumatic brain injury in the rat. Drug Metab Dispos 29:296-298, 2001. 110. Oakley GG, Roe AL, Blouin RA, Twaroski TP, Ganguly TC, Vore M, Lehmler H-J, Robertson LW:

2,4,4’-Trichlorobiphenyl increases STAT5 transcriptional activity. Mol Carcinog 30:199-208, 2001. 111. Warren GW, Van Ess P, Watson AM, Mattson MP, Blouin RA: Cytochrome P450 and antioxidant

activity in interleukin-6 knockout mice after induction of the acute phase response. J Interferon Cytokine Res 21:821-826, 2001.

112. Roe AL, Poloyac SM, Howard G, Shedlofsky SI, Blouin RA: The effect of endotoxin on hepatic nuclear

factor 1 nuclear protein binding: potential implications on CYP2E1 expression in the rat. J Pharm Pharmacol 53:1365-1371, 2001.

113. Van Ess PJ, Pedersen WA, Culmsee C, Rowley D, Mattson MP, Blouin RA: Elevated hepatic and

depressed renal cytochrome P450 activity in the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurochem 80: 571-578, 2002.

33

114. Van Ess PJ, Mattson MP, Blouin RA: Enhanced induction of cytochrome P450 enzymes and CAR

binding in the TNF (p55-/-/p75-/-) double receptor knockout mice following Phenobarbital treatment. J Pharmacol Exp Ther 300: 824-830, 2002.

115. Van Ess PJ, Poloyac SM, Mattson MP, Blouin RA: Blunted induction of hepatic CYP in TNF (p55-/-

/p75-/-) double receptor knockout mice following clofibrate treatment. Pharm Res 19:709-713, 2002. 116. Roche VR, Nahata MC, Wells BG, Kerr RA, Draugalis JR, Maine LL, Abate MA, Brueggemier RW,

DiGate RJ, Drennen JK, Mort JR, Roberts AD, Meyer SM, O'Sullivan TA, Angaran DM, Koh-Knox CP, Richey C, Kroboth PD, Appleby JC, Flynn AA, Alkana RL, Bogner RH, McNamara PJ, Torchilin VP, Oie S, Blouin RA, White HS, Miller KW: Roadmap to 2015: Preparing Competent Pharmacists and Pharmacy Faculty for the Future. Combined Report of the 2005-06 Argus Commission and the Academic Affairs, Professional Affairs, and Research and Graduate Affairs Committees. Am J Pharm Educ 2006 December 15; 70(suppl): S5.

117. Robert A. Blouin PharmD, Richard F. Bergstrom PhD, Vicki L. Ellingrod PharmD, Courtney V. Fletcher

PharmD, Richard D. Leff PharmD, Andrew Morris PharmD, Richard T. Okita PhD, Jeanette C. Roberts PhD, Timothy S. Tracy PhD, Rosalie Sagraves PharmD, and Kenneth W. Miller PhD: Report of the AACP Educating Clinical Scientists Task Force. Am J Pharm Educ 71 (S05): 1-11, 2007.

118. Blouin RA, Joyner, PU, Pollack, GM: Preparing for a renaissance in pharmacy education: The need,

opportunity, and capacity for change. Am J Pharm Educ 72 (2):1-3, 2008. 119. Carter BL, Blouin RA, Chewning BA, Goode J-VR, Lipowski EE, Nelson AA, Schumock GT, Sleath

BL, Miller KW: Report of the AACP Educating Clinical Scientists Task Force II. Am J Pharm Educ 72 (S10): 1-13, 2008.

120. Figg WD, Chau CH, Okita R, Preusch P, Tracy TS, McLeod H, Reed M, Pieper J, Knoell D, Miller K,

Speedie M, Blouin RA, Kroboth P, Koda-Kimble MA, Taylor P, Cohen J, Giacomini: Pharm.D. Pathways to Biomedical Research: The National Institutes of Health Pharmacy Research Conference. Pharmacotherapy 28(7):821-833, 2008.

121. O’Malley MS, Blouin RA, Pisano ED, Rimer BK, Roper WL, Earp HS: Research for North Carolina:

The University Cancer Research Fund. NC Med J 69 (4): 299-302, 2008. 122. Blouin RA, Pollack GM: Training Clinical Pharmaceutical Scientists in Today’s Highly Competitive

Times: It’s Time to Commit to Change. Pharmacotherapy 29 (2) 134-136, 2009. 123. Blouin RA, Riffee WH, Robinson ET, Beck DE, Green C, Joyner PU, Persky AM, Pollack GM: Roles of

Innovation in Education Delivery. Am J Pharm Educ 73 (8): 1-19, 2009. 124. Van Amburgh JA, Surratt CK, Green JA, Gallucci RM, Colbert J, Zatopek SL, Blouin RA: Succession

Planning in US Pharmacy Schools. Am J Pharm Educ 74 (5): Article 86, 2010. 125. Joyner PU, Blouin RA, Mumper RJ: New Directions in Pharmacy Education. JAPhA 51(6): 678-680,

2011.

34

126. Joyner PU, O’Connor SK, Thrasher KA, Blouin RA: Addressing Rural Health Disparities through Pharmacy Curricula. Am J Pharm Educ 76 (10), Article 180, 2012.

127. Parker RB, Ellingrod VL, DiPiro JT, Bauman JL, Blouin RA, Welage LS: Preparing Clinical Pharmacy

Scientists for Careers in Clinical/Translational Research: Can We Meet the Challenge? Pharmacotherapy 33 (12): 337-346, 2013.

128. McLaughlin JE, Dean MJ, Mumper RJ, Blouin RA, McClurg MT: A Roadmap for Educational Research

in Pharmacy. Am J Pharm Educ 77 (10), Article 218, 2013. 129. Roth MT, Mumper RJ, Singleton SF, Lee CR, Rodgers PT, Cox W, McLaughlin, Joyner P, Blouin RA: A

Renaissance in Pharmacy Education at the University of North Carolina at Chapel Hill. NCMedJ 75(1):48-52, 2014.

BOOK CONTRIBUTIONS: Clinical Guide to Laboratory Tests. Norbert W. Tietz; Drugs: Therapeutic and Toxic. W.B. Saunders Co., Philadelphia, PA, l:560-621, 1983. Moyer TP, Pippenger CE, Blanke RV, Blouin RA: Therapeutic Drug Monitoring (Chapter 17): In: Tietz NW ed., Textbook of Clinical Chemistry (Second Edition), W.B. Saunders Co., Philadelphia, PA, 1615-1669, 1986. Moyer TP, Pippenger CE, Blanke RV, Blouin RA: Therapeutic Drug Monitoring (Chapter 26): In: Tietz NW ed., Fundamentals of Clinical Chemistry (Third Edition), W.B. Saunders, Co., Philadelphia, PA, 842-868, 1987. DiPiro JT, Blouin RA, Pruemer J: Concepts in Clinical Pharmacokinetics: A Self Instructional Course: ASHP Publications, 1988. Clinical Guide to Laboratory Tests, Second Edition, Norbert W. Tietz, Therapeutic Drugs. W.B. Saunders Co., Philadelphia, PA, 2; 681-764, 1990. Chandler MHH, Blouin RA: Dietary Influences on Drug Disposition (Chapter 12), Evans WE, Schantag JJ, Jusko WJ eds., Applied Pharmacokinetics Principles of Therapeutic Drug Monitoring (Third Edition), Applied Therapeutics, Spokane, WA, 1992. Blouin RA, Chandler MHH: Special Pharmacokinetic Considerations in the Obese (Chapter 11). In: Evans WE, Schantag JJ, Jusko WJ eds., Applied Pharmacokinetics Principles of Therapeutic Drug Monitoring (Third Edition), Applied Therapeutics, Spokane, WA, 1992. Chandler MHH, Blouin RA: Dietary Influences on Drug Disposition (Chapter 12), In: Burton ME, Shaw LM, Schantag JJ, Evans WE eds., Applied Pharmacokinetics Principles of Therapeutic Drug Monitoring (Fourth Edition), Lippincott, Williams, and Wilkins, Philadelphia, PA, 2006. Blouin RA, Chandler MHH: Special Pharmacokinetic Considerations in the Obese (Chapter 11). In: Burton ME, Shaw LM, Schantag JJ, Evans WE eds., Applied Pharmacokinetics Principles of Therapeutic Drug Monitoring (Fourth Edition), Lippincott, Williams, and Wilkins, Philadelphia, PA, 2006.

35

DiPiro JT, Blouin RA, Pruemer J, Spruill WJ: Concepts in Clinical Pharmacokinetics: A Self Instructional Course - Second Edition, ASHP Publications, 1996. DiPiro JT, Spruill WJ, Blouin RA, Pruemer J: Concepts in Clinical Pharmacokinetics, Third Edition, ASHP Publications, 2002. DiPiro JT, Spruill WJ, Wade WE, Blouin RA, Pruemer J: Concepts in Clinical Pharmacokinetics, Fourth Edition, ASHP Publications, 2005. DiPiro JT, Spruill WJ, Wade WE, Blouin RA, Pruemer J: Concepts in Clinical Pharmacokinetics, Fifth Edition, ASHP Publications, 2010. GRANT ACTIVITY: A. Completed Industrial/Institutional Grants: 1. The Effect of Positive End Expiratory Pressure on the Total Body Clearance of Theophylline in Dogs;

BRSG (College of Medicine), University of Kentucky; November 1977; (Co-investigator), $1,900. 2. Major Research Equipment Fund; UKRF, University of Kentucky; October 1978; (Principal

investigator), $4,600. 3. Bioavailability and Safety Evaluation of Theophylline Sodium Glycinate; Merrell-National Laboratories;

October 1978; (Co-investigator). 4. Aminoglycoside Pharmacokinetics in Obese Patients; UKRF, University of Kentucky; January 1979;

(Principal investigator), $1,700. 5. Pharmacokinetics of Tobramycin in Morbidly Obese Patients; Eli Lilly Co.; May 1978; (Principal

investigator), $1,000. 6. Pharmacokinetics of Amikacin in Morbidly Obese Patients; Bristol Lab; January 1979; (Principal

investigator), $1,200. 7. Evaluation of the Disposition of Theophylline in the Elderly; Sanders Brown Aging Grant, University of

Kentucky; April 1979: (Principal investigator). 8. Evaluation of the Pharmacokinetics of Doxorubicin in Liver Disease; American Cancer Society

Institutional Grant; November 1980; (Co-investigator), $4,800. 9. Evaluation of Amikacin Pharmacokinetics During Pregnancy; UKRF, University of Kentucky;

November 1980; (Principal investigator), $2,800. 10. Evaluation of Obese Animal Model; BRSG (College of Pharmacy), University of Kentucky; September

1981; (Principal investigator), $2,400.

36

11. Acute and Chronic Effects of Right Ventricular Dysfunction on Hepatic Drug Elimination; BRSG

(College of Medicine), University of Kentucky; November 1981; (Co-investigator), $5,000. 12. Obese Rat Model: Physiologic/Pharmacokinetic Implications; Kircher Fund; January 1982; (Co-

investigator), $5,000. 13. Obese Rat Model: Physiologic/Pharmacokinetics Implications; Incentive Award, University of

Kentucky; February 1982; (Principal investigator), $1,000. 14. Hibernation Induction Trigger: Physiologic Effects in the Rat; UKRF, University of Kentucky;

November 1982; (Principal investigator), $2,538. 15. Chemical and Physiological Characterization of a Hibernation Induction Trigger; BRSG (College of

Medicine), University of Kentucky; February 1983; (Co-investigator), $2,000. 16. Tobramycin Bioequivalence in the Eye; Alcon Laboratories; October 1983; (Co-investigator), $6,000. 17. Estrogen Disposition in Obesity-A Link to Cancer; UKMC; October 1984; (Co-investigator), $5,500. 18. Formation and Inactivation of Highly Reactive Intermediate Metabolites in Obesity; UKMC; October

1984; (Principal investigator), $4,500. 19. Estrogen Disposition in Obesity-A Link to Cancer; UKMC Major Research Equipment; November 1984;

(Co-investigator), $8,500. 20. Dose-Bioavailability Relationship of PN200-110 in Healthy Male Volunteers; Sandoz Pharmaceuticals;

November 1984; (Co-investigator), $31,589.50. 21. Bioavailability and Pharmacokinetic Evaluation of Neptazane Tablets; Lederle Laboratories; October

1984; (Co-investigator), $75,110. 22. Bioavailability Study of BW825C, Burroughs Wellcome; April 1985; (Co- investigator), $49,364. 23. Evaluation of the Bioavailability of Two Strengths of PN200-110; Sandoz Pharmaceuticals; April 1985;

(Co-investigator), $52,535. 24. Levothyroxine Bioavailability: In Vivo Comparison, Flint Laboratories; November 1984; (Principal

investigator), $62,829. 25. The Effects of Renal Function on the Disposition of PN200-110, Sandoz Pharmaceuticals, April 1985;

(Principal investigator), $93,528. 26. The Effects of Liver Cirrhosis on the Disposition of Flurbiprofen, The Upjohn Co., April 1985; (Principal

investigator), $40,000. 27. The Disposition of RO1O-9359 and RO10-1670 in an Obese Rodent Model; Hoffmann-LaRoche;

September 1985; (Co-investigator), $16,000.

37

28. Protein Binding of the Aldose Reductase Inhibitor AL1576; Alcon Pharmaceuticals; June 1985; (Co-investigator), $13,800.

29. Extended Multiple-Dose Safety and Pharmacokinetic Study of BW207U and Placebo in Normal Male

Volunteers; Burroughs Wellcome; August 1985; (Co-investigator), $126,514. 30. A Pilot ViskinR Elan 7 Capsule Bioavailability Study in Fasted and Non-Fasted Healthy Male

Volunteers; Sandoz Pharmaceuticals; April 1986; (Co-investigator), $40,615. 31. Dextromethorphan-Mephenytoin: Influence of Co-Administration on Patient Phenotyping; Bristol

Laboratories; April 1986; (Co-investigator), $12,500. 32. Influence of Oxidative Phenotype on Midazolam Disposition; Hoffmann LaRoche; June 1986; (Co-

investigator), $20,0l0. 33. Population Screening for Deficiencies in Oxidative Drug Metabolism; UKMC; October 1986; (Co-

investigator), $6,000. 34. The Influence of Aging on the Stereoselective Disposition of Model Racemic Drugs; UKMC; October

1986; (Principal investigator), $6,743. 35. Protocol to Evaluate the Bioavailability of Two Dosage Forms of TI211-950 Relative to a Reference

Solution in Healthy Male Volunteers; Sandoz Pharmaceuticals; September 1986; (Co-investigator), $77,000.

36. Evaluation of a Computer Software System for the Prediction of Serum Digoxin, Quinidine,

Theophylline, and Aminoglycoside; Abbott Diagnostics; October 1986; (Principal investigator), $8,000. 37. Population Screening for Deficiencies in Oxidative Drug Metabolism; Bristol Laboratories; October

1986; (Co-principal investigator), $22,540. 38. A Bioequivalence and Safety Study of Vancomycin in Normal Adult Male Volunteers; Lyphomed Labs.;

May 1987; (Co-investigator), $47,822. 39. Response of Cardiac Beta Receptors to Propranolol Stereoisomers in the Elderly; BRSG; May 1987;

(Principal investigator), $5,000. 40. The Single Dose Pharmacokinetics of Nefazodone in Extensive and Poor Metabolizer of

Dextromethophan; Bristol Laboratories; September 1987; (Principal investigator); $33,833. 41. Pulmonary Function in Elderly: Response to Theophylline Brochodilation; UKMC; October 1987; (Co-

investigator), $5,000. 42. Age and Verapamil Stereoselective Disposition; Sandoz Foundation for Gerontological Research;

November 1987; (Co-investigator), $25,720. 43. Absolute Bioavailability and Disposition of Fleroxacin in Healthy Subjects and Patients with Liver

Cirrhosis; Hoffmann-LaRoche; July 1988; (Principal investigator), $102,000.

38

44. The Effect of Antacids on the Absorption of Lomefloxacin; G.D. Searle and Co.; October 1988; (Co-investigator), $65,000.

45. Age and Propranolol Enantiomeric Kinetics and Dynamics; UKMC Major Equipment Grant; January

1989; (Principal investigator), $13,965. 46. Evaluation of the Plasma Protein Binding of U-74006F; The Upjohn Co.; March 1989; (Co-investigator),

$49,611. 47. Neonatal Phenobarbital Imprinting in Humans: Effect on the Cytochrome P-450 System; BRSG; May

1989; (Principal investigator), $5,000. 48. A Bioavailability Study of ANSAID (Upjohn) vs. Apo-Flurbiprofen (Apotex) in Normal Adult Male

Volunteers; PTRL(Apotex); August 1989; (Co-investigator), $39,878. 49. The Effect of Renal and Liver Disease on the Serum Protein Binding of Flurbiprofen (Prospective); The

Upjohn Co.; January 1990; (Principal investigator), $35,650. 50. The Effect of Renal and Liver Disease on the Serum Protein Binding of Flurbiprofen (Retrospective);

The Upjohn Co.; June 1990; (Principal investigator), $20,125. 51. The Effect of Obesity on the Disposition of Fleroxacin; F. Hoffmann LaRoche; July 1990; (Principal

investigator), $38,525. 52. Hydrolysis of Cefetamet Pivoxil in Gastric Juices; F. Hoffmann-LaRoche; July 1990; (Principal

investigator), $20,700. 53. Age and Stereoselective Kinetics/Dynamics of Terbutaline; Astra Clinical Pharmacy Research Award;

July 1990; (Co-investigator), $7500. 54. Regulation of Drug Metabolizing Enzymes: Use of Immunoblotting Techniques; UKMC Research Fund:

December 1990; (Co-investigator), $20,000. 55. Major Equipment Grant: Beckman Optima XL-90 Ultracentrafuge Plus Rotors; UKMC Research Fund:

April 1990; (Co-investigator), $71,100. 56. Major Equipment Grant: Packard 1900 TR Liquid Scintillation Analyzer; UKMC Research Fund;

February 1992; (Co-Investigator), $19,208. 57. Major Equipment Grant: Shimadzu UV160 UV-Visible Recording Spectrophotometer with Super Micro

Cell Holder; UKMC Research Fund; February 1992; (Co-Investigator), $8,845. 58. Major Equipment Grant: Tissue Culture Laboratory Equipment; UKMC Research Fund; February 1992;

(Co-Investigator), $8,726. 59. The Effect of Cl284,846 on the Hepatic Cytochrome P-450 Mixed Function Oxidase System; American

Cyanamid Co.; July 1992; (Principal Investigator), $29,336.

39

60. Mechanistic Toxicity Study of Geriatric I. Cl275,838 for Three Months in Rats and Mice; American Cyanamid Co.; October 1992; (Principal Investigator), $45,478.40.

61. Upper Aerodigestive Tract CA: Role of Cytochrome P450, UKMC Research Fund; April 1993;

(Principal Investigator), $12,000.00. 62. Mephenytoin Phenotyping Assay; Wyeth-Ayerst Clinical Pharmacololgy Laboratories; January 1994;

(Principal Investigator), $7,174.40. 63. Pharmacokinetics of venlafaxine in Extensive and Poor Metabolizers of Dextromethorphan; Wyeth-

Ayerst Labs.; May 1994; Principal Investigator), $144,888. 64. Determination of Extensive or Poor Metabolism Status through Phenotypying with Dextromethorphan

and Mephenytoin; Wyeth-Ayerst Clinical Pharmacology Laboratory; September 1994; (Principal Investigator) $16,807.

65. Mechanism of Chloroquine Induced Retinopathy; Pfizer Inc.; February 1999-April 2001; (Principal

Investigator, 5% Effort), $120,130 (Total); $82,000 (direct). 66. NFkB Decoy DNA: Formulation and Liver Targeting; UKMC; July 2000-June 2001; (Principal

Investigator, 5% Effort). $15,000. 67. Research Training in Environmental Toxicology; NIHEH (T32-ES07266-02); July 2000-June 2005; (Co-investigator, 5% effort), $704,392. 68. Alcohol-Induced Hepatic P450 in HCV/HIV Oxidative Injury, NIH (R01-AA012852-02); October 2000-

September 2004; Co-Investigator, 5% effort), $982,590 (Total); $700,000 (Direct). 69. Career Training in Therapeutics & Translational Research; NIH (K30-HL04163-02); October 2000-

September 2005; (Co-Principal Investigator, 25% effort), $1,000,000 (Direct). 70. Nanoplate Engineering of Cell-Specific Nanoparticle, NIH R21/R33 Phased Innovation Award (R21-

EB00531-01); July 2002-June 2004; (Co-Investigator, 5% Effort), $300,864 (Total); R21/R33 Project Period, July 2002-June 2007; Co-investigator, 5%), $1,919,393 (Total).

Foundation Grants: 1. Altered Estrogen Metabolism in Obesity: A Link to Cancer, The Weight Watchers Foundation, Inc.,

March 1985; (Co-investigator), $10,541. 2. The Influence of Aging on the Stereoselective Disposition of Model Racemic Drugs; American Society

of Hospital Pharmacists Research and Education Foundation; July 1986; (Principal investigator; Fellowship preceptor for Mary H. H. Chandler), $18,000.

3. Influence of Rifampin on Age-Related Stereoselective Metabolism of Hexobarbital; UKMC; October

1987; (Principal investigator), $6,178.

40

4. The Influence of Aging and Enzyme Induction with Rifampin on the Stereoselective Disposition of Hexobarbital; American Society of Hospital Pharmacists Research and Education Foundation; July 1988; (Principal investigator; Fellowship preceptor for Deborah A. Smith), $18,000.

5. Terbutaline and the Effects of Age on Beta-2 Adrenoceptor Sensitivity; American Lung Association of

Kentucky; March 1989; (Co-investigator), $17,469. 6. The Effect of Endotoxin and Sepsis on Hepatic Drug Metabolism; American College of Clinical

Pharmacy; July 1992; (Principal Investigator; Fellowship preceptor for Beth Israel); $19,500.

7. The Effect of Head Trauma/Acute Phase Response on Brain and Liver Cytochrome P450 Enzymes (BB-9502-K3); February 1996-December 1999; (Principal Investigator); Kentucky Spinal Cord and Head Injury Research Board; $231,897.

8. CYP2E1 Activity and Transcription Binding in Humans; American College of Clinical Pharmacy; July

1999-Dec 2000; (Principal Investigator, 10%), $10,000 (Direct). Government Grants: 1. Age and Cardiovascular Drug Stereoselective Disposition; NIA (R01 AG07478); July 1988-June 1991;

(Co-investigator, 10% effort), $420,612. 2. Enzyme Induction Defect: Implications for Toxicity; NIH (R01 GM42058); January 1990-December

1992; (Principal investigator, 25% effort); Total Award for Year 1 $157,395. 3. Effects of Cytokines on Hepatic Drug Metabolism; VA Program Project Grant; October 1989-September

1992; (Co-investigator, 5% effort), $237,400. 4. Research Training in Environmental Toxicology; NIHEH (ES07266); July 1990-June 1995; (Co-

investigator, 5% effort), $978,112. 5. Xenobiotic Transfer into Milk-Diffusional Model; NIH; December 1991-November 1995; (Co-

investigator, 5% effort), Total Award for Year 1 $184,745. 6. Effects of Cytokine on Hepatic Drug Metabolism; VA Program Project Grant; October 1992-September

1994; (Co-investigator, 5%), $269,700. 7. Effects of Cytokines on Hepatic Drug Metabolism; VA Program Project Grant; October 1996-September

2000; (Co-investigator, 5% effort), $304,400. 8. Mechanisms of Brain Injury and its Systemic Sequelae; NIH Program Project Grant 5PO1-NS31220;

April 1994-March 1999; (Co-Investigator, 10%), $3,750,000 (Total Project); Approx. $110,000/yr (Altered Hepatic Metabolism following Head Injury).

9. Research Training in Environmental Toxicology; NIHEH (T32-ES07266); July 1995-June 2000; (Co-

investigator, 5% effort), $704,392. 10. North Carolina Translational & Clinical Sciences Institute (NCTRACS): NIH (1UL1TR001111-01);

October 2013-September 2018; (Co-investigator, 5% effort; PI - Dr. Marschall Runge), $5,650,505.

Mail Ballot

Board of Trustees

August 18, 2017

Attached for your review and approval is a memo concerning the terms of appointment and compensation for Dr. Robert A. Blouin as Executive Vice Chancellor and Provost. This mail ballot will be approved as part of the consent agenda at the full board meeting on Thursday, September 28, 2017.

The undersigned votes as follows with respect to the recommendation proposed in Chancellor Folt’s memorandum dated August 18, 2017.

Appointment and compensation for Dr. Robert A. Blouin as Executive Vice Chancellor and Provost.

Approve ☐ Disapprove ☐

Signature________________________________________________________

Printed Name_____________________________________________________

Date_____________________________________

Please fax to Debbie Dibbert at (919) 962-1647 or email to debbie_dibbert@unc.edu.

This ballot was approved by majority vote on August 18, 2017 by the following: Haywood Cochrane, Chuck Duckett, Bill Keyes, Jeff Brown, Lowry Caudill, Julia Grumbles, Kelly Hopkins, Allie Ray McCullen, Ed McMahan, Richard Stevens, Dwight Stone, and Elizabeth Adkins.

MEMORANDUM

TO: Members of the Board of Trustees

FROM: Carol L. Folt

RE: Mail Ballot

DATE: August 31, 2017

You have authorized my office to poll you by mail concerning personnel matters that require attention by the Board. Accordingly, we are transmitting to you herewith personnel actions as follows:

EHRA Faculty Compensation & Tenure Actions Attachment A

Please mark and return the enclosed mail ballot indicating whether or not you agree with the actions proposed. Thank you.

ATTACHMENT B

The University of North Carolina at Chapel HillEXECUTIVE SUMMARY

Board of TrusteesAugust 2017

Appendix A

Page 1

No. College/Division Name Dept./School Current Rank New Rank Tenure Request Reason Effective Date Salary

1 Health Affairs Satish Gopal Medicine Clinical Assistant Professor Associate Professor 6/1/2017 $203,000.002 Health Affairs Nicholas Brown Pharmacology N/A Assistant Professor 9/1/2017 $105,000.003 Academic Affairs Toshihide Hige Biology/Cell Biology & Physiology N/A Assistant Professor 1/1/2018 $77,500.004 Health Affairs Yuchao Jiang Biostatistics/Genetics N/A Assistant Professor 9/1/2017 $120,000.005 Academic Affairs Suzanne Lye Classics N/A Assistant Professor 7/1/2018 $73,000.006 Health Affairs Sriram Machineni Medicine N/A Assistant Professor 9/1/2017 $172,000.007 Academic Affairs William Polacheck BME-UG N/A Assistant Professor 7/1/2018 $90,000.00

8 Health Affairs Katherine Tumlinson Maternal & Child Health N/A Assistant Professor 9/1/2017 $116,000.009 Health Affairs Carmina Valle Nutrition Research Assistant Professor Assistant Professor 9/1/2017 $112,000.00

0Promotion to Full Professor

1 Health Affairs Kristin Reiter Health Policy & Management Associate Professor Professor 9/1/2017 $154,404.00Reappointments to the same Rank

1 Health Affairs John VaValle Medicine Assistant Professor Assistant Professor 9/1/2018 $278,900.00Designation/Reappointments to Departmental Chair

1 Academic Affairs Allen Anderson Music Professor Chair 1/1/2018 $106,067.002 Academic Affairs Mark Crescenzi Political Science Distinguished Term Professor Chair 7/1/2017 $126,000.003 Academic Affairs Richard Superfine Applied Physical Sciences Distinguished Professor Chair 7/1/2017 $156,063.00

Designation/Reappointments to Distinguished Professorship

1 Academic Affairs Ann Anderson Government Associate Professor

Albert and GladysCoates Distinguished Term Associate Professor 9/1/2017 $120,319.00

2 Academic Affairs Willow Jacobson Government Associate Professor

Albert and Gladys Hall Coates Distinguished Term Associate Professor 9/1/2017 $120,942.00

3 Academic Affairs Diane Juffras Government Professor

Distinguished Term Professor 9/1/2017 $133,160.004 Academic Affairs Kate Millonzi Government Professor

Distinguished Term Professor 9/1/2017 $136,766.00

5 Academic Affairs Kimberly Nelson Government Associate Professor

Albert and Gladys Coates Distinguished Term Associate Professor 9/1/2017 $118,368.00

6 Academic Affairs Meredith Smith Government Assistant ProfessorAlbert and Gladys Coates Term Assistant Professor 9/1/2017 $100,255.00

7 Academic Affairs Charles Szypszak Government ProfessorAlbert Coates Distinguished Professor 9/1/2017 $152,767.00

Actions Conferring TenurePromotion Conferring Tenure

1 Academic Affairs Xiaodong Chen Geography Assistant Professor Associate Professor Promotion based on research, teaching and service 1/1/2018 $76,265.003 Health Affairs Stuart Rennie Social Medicine Associate Professor Associate Professor Promotion based on excellence in research 10/1/2018 $115,000.00

New Appointments Conferring Tenure0

Addition of Joint Appointment Conferring Tenure

Personnel ActionsNew Appointments without Tenure

Addition of Joint Appointment without Tenure

The University of North Carolina at Chapel HillEXECUTIVE SUMMARY

Board of TrusteesAugust 2017

Appendix A

Page 2

No. College/Division Name Dept./School Current Rank New Rank Tenure Request Reason Effective Date Salary0

Departmental Transfer1 Academic Affairs Laura Miller Biology/Mathematics* Associate Professor Professor

The University of North Carolina at Chapel HillEXECUTIVE SUMMARY

Board of TrusteesJuly 14, 2014

Appendix B

Page 3

No. College/Division Name School Department Rank Reason

Requested Amount of Increase **

Percent of Increase **

June 30 Salary

Current Salary New Salary *

Effective Date

1 Academic Affairs Samuel Amago Arts & Sciences Romance Studies Distinguished Term Professor/ChairIncrease due to participation in the Academic Leadership Program $45,779 35.38% $129,403 $166,965 $175,182 8/1/2017

2 Academic Affairs Lorraine Aragon Arts & Sciences Asian Studies Adjunct Associate Professor

Increase due to new secondary appointment as Adjunct Associate Professor in the Department of Asian Studies $15,000 29.95% $50,084 $50,084 $65,084 7/1/2017

3 Health Affairs Linda Beeber Nursing ProfessorIncrease due to new secondary administrative appointment as Assistant Dean for the PhD Division $15,000 9.04% $165,905 $165,905 $180,905 8/15/2017

4 Health Affairs Charles Bush Medicine Orthopaedics Clinical Associate Professor

Increase due to new administrative appointment as Fellowship Director of the Orthopaedics APP Fellowship $25,000 25.64% $97,503 $112,503 $122,503 8/1/2017

5 Health Affairs Gaurav Dave Medicine Internal Medicine Research Assistant Professor

Increase due to new secondary administrative appointment as Associate Director of the Center for Health Equity and Research $20,000 19.94% $100,292 $100,292 $120,292 8/1/2017

6 Health Affairs Cheryl Giscombe Nursing Associate ProfessorIncrease due to new secondary administrative appointment as Assistant Dean for the MSN Division $15,000 11.77% $127,493 $127,493 $142,493 8/15/2017

7 Academic Affairs Jacqueline Hagan Arts & Sciences Sociology Distinguished Professor Increase based on internal equity $26,011 22.23% $116,989 $135,489 $143,000 8/1/2017

8 Academic Affairs Martinette Homer Education Clinical Assistant Professor

Increase due to new secondary administrative appointment as Regional Director of the NC New Teacher Support Program $10,000 9.29% $107,611 $107,611 $117,611 7/1/2017

9 Academic Affairs Thomas Kash Medicine Pharmacology Distinguished Professor

Increase due to new secondary administrative appointment as Vice Chair for Faculty Development in the Department of Pharmacology $10,000 5.97% $167,475 $167,475 $177,475 9/1/2017

10 Health Affairs Ching-Chang Ko Dentistry Orthodontics ProfessorIncrease based on retention, as Dr. Ko is being actively recruited by Indiana University $42,945 19.79% $217,055 $217,055 $260,000 9/1/2017

11 Health Affairs Shu Wen Ng Public Health Nutrition Research Associate ProfessorIncrease due to new appointment as Associate Professor via external competitive event $17,420 14.99% $116,180 $116,180 $133,600 9/1/2017

12 Health Affairs Whitney Robinson Public Health Epidemiology Assistant Professor Increase due to promotion to Associate Professor $18,820 17.24% $109,180 $109,180 $128,000 9/1/2017

13 Health Affairs Shielda Rodgers Nursing Clinical Associate Professor

Increase due to new secondary administrative appointment as Assistant Dean for Inclusive Excellence $15,000 16.97% $88,397 $88,397 $103,397 8/15/2017

14 Health Affairs Andrew Smitherman Medicine Pediatrics Post Doc Research AssociateIncrease due to new appointment as Clinical Assistant Professor via external competitive event $87,751 140.97% $62,249 $62,249 $150,000 7/3/2017

15 Academic Affairs Sarah Beth Verbiest Social Work Clinical Associate Professor

Increase due to new secondary administrative appointment as Director of the Jordan Institute for Families $10,000 10.00% $99,976 $99,976 $109,976 9/1/2017

16 Academic Affairs Sharon Holland Arts & Sciences American Studies ProfessorIncrease due to being appointed as the Townsend Ludington Term Distinguished Endowed Professor $7,500 5.16% $145,209 $145,209 $152,709 7/1/2017

171819202122232425

No. College/Division Name Department/School Rank Reason

Total Monetary Value of Non-

Salary Compensation

Duration of Non-Salary

Compensation Effective Date End Date

Non-Salary Compensation Actions0 N/A N/A N/A N/A N/A N/A N/A N/A N/A NA

Compensation Actions*Available funding for each action has been confirmed by the appropriate Department and School/Division management officials to support the proposed salary increase. Upon implementation, specific funding sources are reviewed and approved at the Department level, as well as by the applicable University Central financial offices, including the University Budget Office and the Office of Sponsored Research for grant-funded salaries.

** Based on cumulative increase(s) to 6/30 salary

The University of North Carolina at Chapel HillEXECUTIVE SUMMARY

Board of TrusteesJuly 14, 2014

Appendix C

Page 4

No. College/Division Name Department/School Rank Description

0 N/A N/A N/A N/A N/A

For Information

No. College/Division Name Department/School Rank Reason

Requested Increase Amount

Percent of Increase

Current Salary New Salary

Effective Date

No. College/Division Name Department/School Rank Reason

Total Monetary

Value of Non-Salary

Compensation

Duration of Non-Salary

Compensation

Effective Date End Date

1 N/A N/A N/A N/A N/A N/A N/A N/A N/A NA

Compensation Actions

Non-Salary Compensation Actions

Mail Ballot

Board of Trustees

August 31, 2017

Chancellor Carol Folt submits for your review and approval the EHRA Faculty compensation and tenure actions as recommended for August 2017. This mail ballot will be approved as part of the consent agenda at the Full Board meeting on Thursday, September 27, 2017.

The undersigned votes as follows with recommendation to these proposed actions as presented by the Chancellor.

Approve Disapprove

EHRA Faculty Compensation and Tenure Actions (Attachment A)

Signature

Printed Name

Date

Please fax to TJ Scott at (919) 962-1647 or email at tj_scott@unc.edu

The following mail ballot was approved by majority vote on August 31, 2017 by the following: Haywood Cochrane, Chuck Duckett, Lowry Caudill, Julia Grumbles, Allie Ray McCullen, Ed McMahan, Hari Nath, Richard Stevens, Elizabeth Adkins. Trustee Dwight Stone recused himself from the vote.

MEMORANDUM

TO: Members of the Board of Trustees

FROM: Carol L. Folt

RE: Mail Ballot

DATE: September 12, 2017

You have authorized my office to poll you by mail concerning personnel matters that require attention by the Board. Accordingly, we are transmitting for your review and approval the following salary adjustment recommendations resulting from the EHRA employee annual raise process.

According to General Administration regulations, the Board of Trustees must approve any increase (regardless of amount) for any SAAO Tier I Vice Chancellor or Provost.

Please mark and return the enclosed mail ballot indicating whether or not you agree with the actions proposed. Thank you.

ATTACHMENT C

O F F I C E O F T H E E X E C U T I V E V I C E C H A N C E L L O R

A N D P R O V O S T

2 1 8 S O U T H B U I L D I N G T 9 1 9 - 9 6 2 - 1 0 9 1 C A M P U S B O X 8 0 0 0 F 9 1 9 - 9 6 2 - 2 4 3 7

C H A P E L H I L L , N C 2 7 5 9 9 - 8 0 0 0

MEMORANDUM

To: Annual Raise Process (ARP) Listserv

From: Barron Matherly, Assistant Provost for Finance

Ann Lemmon, Assistant Provost for Human Resources

Linc Butler, Associate Vice Chancellor for Human Resources

Re: Fiscal Year 2017-18 EHRA Faculty and Non-Faculty ARP Guidelines

Date: August 18, 2017

As you know, the state budget has been approved for FY2017-18 and includes legislative increase (LI)

funding for EHRA employee annual salary increases. The LI funds for all EHRA employees will be

pooled and allocated to MOUs for use in the ARP. In addition to the funds allocated thru the LI

process, the Chancellor has directed that a minimum of 1.0% of each MOUs EHRA Faculty state

funded salary base for filled positions be used to fund annual salary increases for EHRA Faculty

employees only.

Policy Guidelines (PG)

1. For EHRA Faculty employees, the ARP must be completed and, at a minimum, include all of

the LI allocations and the Chancellor directed MOU 1% funding requirement.

2. For EHRA Non-Faculty employees, the ARP must be completed and, at a minimum, include all

of the LI allocations.

3. Use of MOU/departmental existing resources other than the Chancellor directed MOU 1%

funding requirement is optional.

4. The ARP applies to permanent full-time and part-time EHRA employees who were in active

employment status as of January 1, 2017, and remain active in the month that the ARP increase

is paid.

5. Temporary EHRA employees are not eligible for the ARP.

6. Any ARP increase must be awarded on an individual employee basis at management’s

discretion. There are no employee entitlements and the ARP cannot be implemented across-

the-board.

7. Any ARP increase must be based on the following criteria:

Individual meritorious performance (including teaching, service, publications, and/or

research productivity for faculty).

Retention of key or hard to recruit personnel.

Secondary criteria that may be considered include equity and labor market.

8. The ARP will be calculated on the June 30, 2017, base salary and included in the September

payroll retroactive to July 1, 2017.

9. Any individual ARP increase for fiscal year 2017‐18 shall not result in a new base salary that is

greater than 4.99% of the June 30, 2017, base salary.

10. Any base salary adjustments made effective July 1, 2017, to date will count toward the ARP

cap of 4.99%. For example, if an employee has already received a 3% increase in this fiscal

year prior to the ARP, only 1.99% remains eligible for an ARP increase. If an employee has

received greater than 4.99% in the current fiscal year prior to the ARP, then there is no

eligibility for any ARP increase amount.

11. Previously approved faculty rank promotions do not count toward the ARP 4.99% cap.

12. Annual salary adjustments tied to BOT and/or BOG approved faculty incentive pay plans or

other special BOT/BOG approved special compensation plans do not count toward the ARP

4.99% cap and should follow the provisions of those plans.

13. Supplemental payments are not part of the base salary and therefore excluded from the ARP.

14. Faculty who entered Phased Retirement on July 1, 2017, are not eligible for the ARP.

However, faculty members who entered the Phased Retirement Program in prior years are

eligible for an ARP increase based on annual evaluations.

15. Employees who are on leave without pay are eligible to receive an ARP increase upon

returning to work.

16. An ARP increase may not exceed an established EHRA employee salary range.

17. Salary increases for EHRA Non-Faculty Research employees in positions assigned to Levels 1,

2 or 3 in the Social Sciences Research, Health Sciences Research and Physical Sciences

Research job families may not result in a salary that exceeds the reference rate of the next

highest job level within the same job family.

18. Salary increases for EHRA Non-Faculty Research employees in positions assigned to Level 4

may not result in a salary that exceeds the job level maximum.

19. Salary increases for EHRA Non-Faculty Instructional and Public Service employees may not

result in a salary that exceeds the job level maximum.

20. Salary increases for EHRA Non-Faculty Senior Academic Administrative Officers (Tier I and

II) may not result in a salary that exceeds the job level maximum.

21. No ARP increase can be officially communicated to EHRA employees until authorization is

provided by the Academic Personnel Office (for EHRA Faculty employees) or the Office of

Human Resources (for EHRA Non-Faculty employees).

22. All ARP increases must be specifically included in the relevant quarterly salary increase report

provided to UNC-General Administration. It is possible that we may also need to provide a

summary of ARP activity in advance of the quarterly reporting cycle if GA receives a time

sensitive request for this information.

23. All post-ARP salary increase actions must be processed on a current basis and per regular

salary increase procedures.

Operational Guidelines (OG)

1. The Office of Budget, Planning and Analysis will communicate information regarding the

distribution of LI allocations and the Chancellor directed MOU 1% funding requirement for

EHRA Faculty annual salary increases early during the week of August 21, 2017.

2. The Academic Personnel Office (EHRA Faculty HR) and the Office of Human Resources

(EHRA Non-Faculty HR) each will distribute a spreadsheet identifying permanent EHRA

employees by School/Division to all School/Division HR Officers and MOU Leads

approximately August 18, 2017. The spreadsheets will require entries related to the proposed

ARP salary increase for each EHRA employee receiving an increase. School/Division HR

Officers and MOU Leads should work together to complete the spreadsheets.

3. Upon completion, the spreadsheets should be signed by the Dean, Vice Chancellor or designee,

and returned to the Academic Personnel Office (for EHRA Faculty employees) at apo@unc.edu

or to the Office of Human Resources (for EHRA Non-Faculty employees) at

epanfsalaryrequest@unc.edu by August 30, 2017. School/Division HR Officers and/or MOU

Leads will be contacted regarding any spreadsheet discrepancies.

4. The completed spreadsheets will be reflected in ConnectCarolina approximately

September 14, 2017. September salary sources will be used to fund the retroactive

payment.

5. School/Division HR Officers and MOU Leads should work together to implement the ARP for

their areas of responsibility within the indicated timeframe. This includes communication

between campus units that have EHRA employees with primary and secondary appointments.

6. Retroactive funding swaps can be made beginning September 28, 2017 by using the Payroll

Accounting Adjustment Tool (PAAT).

ARP listserv subscribers will receive necessary updates during the ARP. MOU Leads and

School/Division HR Officers and Secondary Contacts who are not already subscribed to the listserv

should contact Karen Stone at karen_stone@unc.edu regarding subscribing (and unsubscribing) to the

ARP listserv. ARP users in the College of Arts & Sciences, School of Medicine, School of Public

Health, and Vice Chancellor for Research (VCR) do not subscribe to the ARP listserv but receive ARP

related communications from their dean’s office or Office of the VCR.

Please see the attached detailed instructions regarding the FY2017-18 ARP implementation,

including processing actions in ConnectCarolina during the ARP.

Attachment

c: Dwayne Pinkney, Senior Associate Vice Chancellor for Finance & Administration and CFO

Wendy Andrews, ARP Steering Committee (Co-lead)

Vanessa Ragland, ARP Steering Committee (Co-lead)

Dave Turner, ARP Steering Committee (Co-lead)

ARP Steering Committee

SAAO Tier I ARP Increases

Proposed for 2017 - 2018

Name Title

Annual

Base Rate

as of

6/30/17

Annual

Supplement/

Bonus

Total Salary

of All Jobs

Proposed ARP

Base Salary

Total

Supplements

PROPOSED

ARP %

Increase

PROPOSED

ARP $$

Increase

Proposed

Total Salary

Ater ARP Comments

Range

Min

Market Rate

(75th

percentile)

Range

Max

CONE, JUDITH ANN

VC, Innovation,

Entrepreneuriship &

Economic Development 310,854.00 0 310,854.00 318,625.35 0 2.50% 7,771.35 318,625.35 Increase based on meritorius perf 231151 346727 462303

CRISP, WINSTON B VC, Student Affairs 330,382.50 0 330,382.50 338,642.06 0 2.50% 8,259.56 338,642.06 Increase based on meritorius perf 185421 278131 370842

CURRAN, JOEL GREGORY VC, Communications 345,303.00 0 345,303.00 355,662.09 0 3.00% 10,359.09 355,662.09 Increase based on meritorius perf 179577 269366 359155

FAJACK, MATTHEW

VC, Finance &

Administration 355,107.90 0 355,107.90 363,985.60 0 2.50% 8,877.70 363,985.60 Increase based on meritorius perf 228398 342597 456796

KIELT, CHRISTOPHER L.

VC, Information

Technology Services 344,998.50 0 344,998.50 358,798.44 0 4.00% 13,799.94 358,798.44 Increase based on meritorius perf 211843 317765 423686

MERRITT, MARK WILLIAM VC and General Counsel 437,349.00 0 437,349.00 452,656.72 0 3.50% 15,307.22 452,656.22 Increase based on meritorius perf 229608 344412 459215

ROUTH, DAVID SHELDON

VC, University

Development 428,989.75 107247 536,236.75 444,004.39 0 3.50% 15,014.64 551,251.39 Increase based on meritorius perf 286053 429079 572106

WASHINGTON, FELICIA

VC, Workforce Strategy,

Equity & Engagement 365,552.25 0 365,552.25 376,518.82 0 3.00% 10,966.57 376,518.82 Increase based on meritorius perf 217854 326781 435708

MAGNUSON, TERRY VC, Research 297,973.55 169450 467,423.55 306,912.76 169450 3.00% 8,939.21 476,362.76 Increase based on meritorius perf 231873 347809 463746

Mail Ballot

Board of Trustees

September 12, 2017

Chancellor Carol Folt submits for your review and approval the SAAO Tier 1 EHRA employee annual raise process increases. This mail ballot will be approved as part of the consent agenda at the Full Board meeting on Thursday, September 27, 2017.

The undersigned votes as follows with recommendation to these proposed actions as presented by the Chancellor.

Approve Disapprove

SAAO Tier 1 EHRA employee annual raise process increases

Signature

Printed Name

Date

Please fax to TJ Scott at (919) 962-1647 or email at tj_scott@unc.edu

The following mail ballot was approved by majority vote on September 12, 2017 by the following: Haywood Cochrane, Chuck Duckett, Jeff Brown, Lowry Caudill, Julia Grumbles, Allie Ray McCullen, Ed McMahan, Hari Nath, Richard Stevens, Dwight Stone, and Elizabeth Adkins.

ATTACHMENT D

ELECTION OF MEMBERS TO THE BOARD OF TRUSTEES OF THE ENDOWMENT FUND AND THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL FOUNDATION, INC.

North Carolina General Statute 116-36 and Board of Governors’ regulations require that the Board of Trustees elect the membership of the Endowment Board of Trustees. There are three (3) vacancies. Attached is a chart showing the names and terms of the current Endowment Trustees. The nominees for each vacancy are shown in bold on the chart.

The Bylaws of The University of North Carolina at Chapel Hill Foundation, Inc. (“Foundation”) require that the Board of Trustees elect two (2) members from the Board of Trustees and three (3) members from the Endowment Board of Trustees to serve on the Board of Directors of the Foundation. There are two (2) vacancies. Attached is a chart showing the names and terms of the current Foundation board.

RECOMMENDED ACTION

A motion to elect Dwight Stone, David Carroll and John Ellison to the Board of Trustees of the Endowment Fund and Dwight Stone and Michael Kennedy to the Board of Directors of The University of North Carolina at Chapel Hill Foundation, Inc.

THE BOARD OF TRUSTEES OF THE ENDOWMENT FUND OF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

MEMBERSHIP – MINIMUM 6; MAXIMUM 9

(three year term)*

MEMBERS ELECTED BY BOARD OF TRUSTEES TERM Haywood Cochrane, Chairman Board of Trustees (Ex-Officio) Carol Folt, Chancellor (Ex-Officio) Dwight Stone (Ex-Officio) (vacancy created by election of Haywood Cochrane as Chairman of the Board of Trustees) Sallie Shuping-Russell 2018 Willard J. Overlock, Jr. 2018 Steve Lerner 2019 Michael Kennedy 2019 David Carroll 2020 (vacancy created by expiration of term of David Carroll) John Ellison 2020 (vacancy created by expiration of second term of Max Chapman) _____________________ * Effective with appointments after July 26, 1996, individuals are eligible for a maximum of two consecutive 3 year terms. Individuals are eligible for reappointment after one year has elapsed from conclusion of most recent term. September, 2017

BOARD OF DIRECTORS OF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL FOUNDATION, INC.

17 MEMBERS; METHOD OF SELECTION

I. NINE EX-OFFICIO MEMBERS

A. 4 BY VIRTUE OF OFFICE (term concurrent with office tenure)

Chair of the Board of Trustees (Haywood Cochrane)

Chancellor (Carol Folt) Vice Chancellor for Finance and Administration (Matt Fajack) Vice Chancellor for University Advancement (David Routh)

B. 2 ELECTED BY BOARD OF TRUSTEES FROM BOARD OF TRUSTEES MEMBERSHIP (term concurrent with Board tenure)*

Dwight Stone 2021 (vacancy created by election of

Haywood Cochrane as Chairman of Board of Trustees)

Julia Sprunt Grumbles 2019

C. 3 ELECTED BY BOARD OF TRUSTEES FROM MEMBERSHIP OF THE BOARD OF TRUSTEES OF THE ENDOWMENT FUND (term concurrent with Endowment tenure)*

Michael Kennedy 2019 (vacancy created by expiration of second term of Max Chapman) Sallie Shuping-Russell 2018 Steve Lerner 2019

II. EIGHT DIRECTORS ELECTED BY THE NINE EX-OFFICIO DIRECTORS

(four year term) David Pardue 2017 Kel Landis 2017 Nelson Schwab 2018 Roger Perry 2018 David Carroll 2019 Ed Fritsch 2019 John Townsend 2020 Williard J. Overlock, Jr. 2020 September, 2017

Risk Assessment and Internal Audit Plan 2017/18

Attachment E

Risk Assessment and 2017/18 Internal Audit Plan - Page 2

Table of Contents

Introduction………………………………………………………………………………….. 3 Risk Assessment Process…………………………………………………………………..... 4 Appendices: A: Calculation of Available Work Hours B: 2017/18 Audit Work Schedule

Risk Assessment and 2017/18 Internal Audit Plan - Page 3

Introduction

Each year, the Internal Audit Department of the University of North Carolina at Chapel Hill develops an audit work plan based on a university-wide assessment of risk. This approach is in keeping with the Institute of Internal Auditors’ International Standards for the Professional Practice of Internal Auditing (IIA Standards) and the Internal Audit Act (NCGS § 143-746) which requires internal audit functions in NC State agencies and institutions to comply with the IIA Standards. Also, basing audit work plans on risk helps ensure that audit resources are allo-cated effectively and efficiently and in a way that best helps manage and the Board of Trustees provide governance and fulfill the University’s mission. The primary objectives of the risk assessment process are to: • Ensure compliance with IIA Performance Standard 2010 – Planning which states: “The

chief audit executive must establish risk-based plan to determine the priorities of the internal audit activity, consistent with the organization’s goals” and with North Carolina’s Internal Audit Act;

• Gather information about the organizational structure of the University, its operations, and its finances and about trends and recent concerns in higher education;

• Identify risk concerns of University management and members of the Finance, Infrastruc-

ture, and Audit Committee of the Board of Trustees and expectations of the Internal Audit Department;

• Identify opportunities to coordinate work with other audit groups, such as the Office of the

State Auditor, to reduce the potential for duplicative audits. • Develop an audit work plan based on risks and opportunities identified during the assess-

ment process; and

• Present the work plan and results of the risk assessment to the Chancellor of the University of North Carolina at Chapel Hill and the Finance, Infrastructure, and Audit Committee of its Board of Trustees for review and approval.

While the initial work plan is developed based on a formal risk assessment process, risks change throughout the year. Therefore, we monitor changes at the University and in higher education during the year and make revisions the work plan as needed.

Risk Assessment and 2017/18 Internal Audit Plan - Page 4

Risk Assessment Process The risk assessment and audit planning process involves developing an audit universe and con-sidering how different components of risk affect individual auditable units and the University as a whole. Audit Universe Development Model

Risk Components 1. Strategic risks – relate to mission and goals of the University 2. Financial risks – relate to stewardship and safeguarding of resources 3. Operational risks – relate to processes used to achieve mission and goals 4. Compliance risks – related to laws, rules, regulations, and other requirements 5. Reputational/service risk – relate to public image and the impact of service failure

Management Input

Issues in Higher Education

Mission, Goals, Objectives, Strategic Planning

Compliance Requirements

Core Business Functions

Individual Units

Information Technology

Risk Assessment and 2017/18 Internal Audit Plan - Page 5

Step 1: Update and Create Audit Universe

The risk assessment process begins with a review of the organization structure of the University and the identifying by various missions, functions, and financial activities of individual depart-ments and other units. What these units are here to do and how they seek to accomplish their mission, goals, etc. forms the base of the audit universe.

• We initially identified functions and activities that are unique to a particular department and activi-

ties that cross departmental lines. Examples include governance practices, the service-related ac-tivities of the Registrar’s Office, various elements of sponsored award management, facilities ser-vices, parking and transportation, etc. These functions/activities become individual audit units.

• We also created audit units for each core business function such as payroll, small order purchasing,

travel, etc. Responsibility for core business functions is shared by departments and central offices; this shared responsibility affects both the risks associated with the core business functions and how they are best audited. We audit core business functions university-wide – an approach that includes an assessment of processes in central offices as well as in a sample of individual units. We believe this approach provides a “birth to death” review that can best identify gaps in or redundancies in internal controls.

• To supplement audits of core business functions, major functions, we also choose to do audit work in individual departments and other units. Departmental audits provide a way to more closely assess risks and governance across the University, to build additional working relationships with the cam-pus community, and potentially to identify control weaknesses before these become problems.

• Although some elements of the audit universe are based on internal factors, external compliance

requirements are major issues in the University’s risk and operating environment. The University has overall policies and procedures that govern how to comply with requirements. In many cases, one or more central units have primary responsibility for monitoring compliance. Since most com-pliance activities are overseen, centrally, we believe that they are best audited university-wide.

• Information technology (IT) supports and enables nearly all functions and activities of the Univer-sity. IT has unique audit and business risks such as disaster recovery, data and physical security, patching, access controls, change controls, data retrieval and reporting, etc. IT at the University is a hybrid function with central systems and servers managed by Information Technology Services and departmental/school servers and systems managed by those units. The IT portion of our audit universe includes a combination of audits of central systems, governance, and policy. We will as-sess issues related to departmental/school systems through general controls review done as part of broader audits of these units.

• Some schools, departments, and centers have unique activities or IT systems. In addition, the highly decentralized nature of the University makes it necessary to include individual units in our audit universe. This practice provides a way to assess, on a more granular level, activities and potential

Risk Assessment and 2017/18 Internal Audit Plan - Page 6

risks across the University. The audits will also provide an opportunity to share information with individual units and to keep the University community aware of Internal Audit as a resource for advice and guidance.

• The final steps in developing an audit universe involve tapping into and leveraging the knowledge of colleagues at other universities and of key members of University management. These individ-uals are a valuable resource for identifying any need to adjust audit units or approaches to better address current and future risks.

Step 2: Assess Risk • Interview the Chairman of the Finance, Infrastructure, and Audit Committee of the Board

of Trustees and key members of University management to identify their views of chal-lenges and opportunities for the University and to get suggestion for items to be included in the audit work plan;

• Consider risk factors: - Significance of operations; - Impact of a service delay or failure; - Sensitivity of information managed; - Public or political sensitivity; - Extent of regulation; - Changes in management or the operating environment; - Key Performance Indicators calculated each month for the UNC Business Compliance

Program; and - Amount of time since any prior audits (internal of external) and the status of findings

from any prior audits; and

• Assign relative risk to auditable units: high, medium, or low risk. Step 3: Develop Audit Work Plan Determine available audit hours based on size of audit staff, available work hours per staff member, and estimates of time for administrative activities such as training, meetings, and leave. Refer to Appendix A for the calculation of available audit hours. Allocate blocks of time for unplanned audits, investigations, advisory work, and annual pro-jects.

Risk Assessment and 2017/18 Internal Audit Plan - Page 7

To select items for the rest of the 2017/18 audit work schedule we considered: • Available audit hours;

• Projects from the 2016/17 audit work plan that needed to be carried forward;

• Specific requests by management or members of the Board of Trustees;

• Nature and timing of any recent or anticipated changes in an area (such as a system conver-sion, new financial management, extensive process revisions, etc.); and

• Recent events at the University and at other colleges and universities that have raised the visibility and sensitivity of certain activities.

After possible units for the 2017/18 audit work schedule were selected, hours were budgeted for each project based on nature of the area audited and the anticipated audit work in an area. If necessary, possible units were added or dropped in order to have a work plan that fit available hours. Refer to Appendix B for the 2017/18 Audit Work Plan. Step 4: Finalize the Work Plan Submit the risk assessment to the Chancellor and Finance, Infrastructure, and Audit Committee for review and approval. Submit the approved plan to General and Administration and the Council of Internal Auditing for their records.

Budgeted

Total Hours Available - Permanent Staff -1- 14,560 Add: Projected temporary employees 600 Less: Vacancies -2- (3,120)

Adjusted hours available 12,040

Less: Leave Hours -3- (1,904) Less: Other Administrative Time -4- (1,698)

Available for projects 8,439

Routine Audits & Annual Projects 3,860 Audit Related 2,100 Special Reviews & Management Requests 2,500

Total Scheduled 8,460

Under/<Over>scheduled ** (22)

-1- = seven postions, 2080 hours each -2- = one postion projected to be filled by 12/31/17 (1,040 hours vacant); one one position with insufficient funding to fill (2,080 hours)-3- = based on official holidays and past use of vacation and sick leave-4- = training, audit committee activities, meetings, professional reading, etc.

Appendix A UNC Internal Audit Available Hours - 2017/18

HoursRoutine Audits Budgeted

Historically Under-utilized Business Program 150 Cleary Act Reporting 300 Governance - Trustee Orientation 400 Follow-up for Prior Internal Audit Findings 860 Follow-up for OSA IT GC Audit 250 Chemistry - departmental audit 400 Athletics Ticket Sales 400 Building Access 400 Energy Services Equipment 400

Total for Routine Audits 3,560

Annual Projects

UNC Business Compliance Program 2018 50 2017/18 Risk Assessment and Audit Plan 200 2017 State Audit 50

Total for Annual Projects 300

Audit Related

Office Systems 500 Internal QAR 250 Audit Committee 100 KPI Reporting 20 HIPAA Security Liaisons 80 Data Access and Reporting 250 UCPPD 100 Policy Liaisons 50 Enterprise Data Coordinating Committee 50 Other Audit Related 200

Total for Audit Related 1,600

Unplanned Projects 3,000

Total Hours Scheduled 8,460

Total Hours Available (8,439) < Under>/Over Scheduled 22

Approvals:Chancellor: ______________________________________________ Date: _______________

Chairman: ______________________________________________ Date: _______________Finance, Infrastructure, and Audit Committee

Appendix BUNC-CH Internal AuditAudit Schedule - 2017/18

9/28/17

9/28/17

Pro-Rated Hours Variance BudgetedBudgeted Budget -5- Charged (Over)/Under Percent

Total Hours Available -1- 14,560 n/a n/a n/aAdd: Projected temporary staff 600 n/a n/a n/aLess: Vacancies -2- (3,120) n/a n/a n/a

Adjusted hours available 12,040

Less: Leave (1,904) (159) 143 16Less: Other Administrative Time -3- (1,698) (141) 172 (31)

Total for Training, Leave, & Administrative (3,602) 300 315 29.9%

Hours Available for Projects 8,439

Routine Audits & Annual Projects 3,860 322 365 (44) 32.1%Audit Related -4- 2,100 175 119 56 17.4%Unplanned Projects and Advisory Work 2,500 208 281 (73) 20.8%

Total Scheduled/Charged 8,460 705 766

Under/<Over> Scheduled (22) 1,081

-1- = seven staff members at 2080 hours/year-2- = one postion projected to be filled by 12/31/17 (1,040 hours vacant); one position with insufficient funding to fill (2,080 hours)-3- = training, audit committee activities, meetings, professional reading, etc.

-4- = consulting and advisory work, activities that improve audit operations.-5- = budget pro-rated for four weeks

UNC Internal AuditUse of Audit Resources

Summary of Audit Hours Used - FY 2018 as of 08/06/17

Page 1 of 1

Planned Audits

In Process

Historically Under-utilized Business ProgramCleary Act ReportingFollow-up for Prior Internal Audit Findings

Scheduled

Governance - Trustee OrientationFollow-up for OSA IT GC AuditChemistry - departmental auditAthletics Ticket SalesBuilding AccessEnergy Services Equipment

Annual Projects

UNC Business Compliance Program 20182017/18 Risk Assessment and Audit PlanSACS 20182017 State Audit

Audit Related

Audit ManualTime SystemOffice SystemsAudit PlanningAudit CommitteeMedia RequestsInternal QARIT Governance Committee & Data Custodian WorkKPI ReportingBoard of Governors' MeetingsHIPAA Security LiaisonContinuous AuditingUniversity Committee on the Protection of Personal DataPrivacy LiaisonData Access and ReportingEnterprise Data Coordinating Committee

Special Projects & Management Requests

CompleteCarolina Center for Educational ExcellenceLaw - Center for Civil RightsSchool of Law - Teaching Loads

In ProcessNutrition Research InstituteLineberger Cancer Center Tissue Culture FacilityJournalism - Fair Labor Standards Act

Multiple Short-term Advisory Projects

Status of 2017/18 Audit Schedule as of 08/06/17UNC Internal Audit

ATTACHMENT F

SITE APPROVAL – SCIENCE COMPLEX PHASE 3

This project will provide advance planning for the redevelopment of the Naval Armory site and adjacent parking lot for a new 220,000 square foot building to house facilities for Applied Physical Sciences, Institute for Convergent Science and innovation space for faculty start-ups.

The anticipated project budget is $175 million.

RECOMMENDED ACTION:

A motion to approve the site.

Science Complex Phase III

Site Approval

2006 CAMPUS MASTER PLAN

N

PROJECT LOCATION

Site Approval

CAMPUS MAP

N

PROJECT SITE

Science Complex Phase III

ATTACHMENT G

SITE APPROVAL –TRANSLATIONAL RESEARCH BUILDING

This project will construct a new approximately 140,000 sf building that will consolidate existing vivarium facilities and allow for additional program growth.

The relocation of the grounds facilities and subsequent demolition of the existing facilities will be part of this project.

The anticipated project budget is $133 million.

RECOMMENDATION ACTION:

A motion to approve the site.

Translational Research Building

Site Approval

2006 CAMPUS MASTER PLAN

N

PROJECT LOCATION

Site Approval

CAMPUS MAP

N

PROJECT SITE

Translational Research Building

ATTACHMENT H

DESIGNER SELECTION – KENAN CENTER 2nd FLOOR AND MCCOLL BUILDING 4th FLOOR RENOVATIONS

This project will renovate selected areas of the Kenan Center and the Kenan Flagler Business School to convert under-utilized rooms and public spaces into open office areas for administrative personnel and faculty.

The project budget is $1,325,293 and will be funded by an institutional trust fund supported by Business School operations.

The project was advertised on August 3, 2017. The Selection Committee received seven (7) proposals.

Three (3) firms were interviewed on September 5, 2017. The Selection Committee consisted of members from the Kenan Flagler Business School and Facilities Planning & Design. The committee recommended the selection of the three firms in the following priority order:

1. CJMW Architecture Winston-Salem, NC

2. 310 Architecture + Interiors Raleigh, NC

3. Allison Blanks Architect Pittsboro, NC

The firms were selected for their past performance on similar projects, strength of their consultant team and experience with campus projects.

RECOMMENDED ACTION:

A motion to approve the three firms in the following priority order:

1. CJMW Architecture Winston-Salem, NC

2. 310 Architecture + Interiors Raleigh, NC

3. Allison Blanks Architect Pittsboro, NC

KFBS Renovations 2nd & 4th Floors

Designer Approval

2006 CAMPUS MASTER PLAN

N

PROJECT LOCATION

KFBS Renovations 2nd & 4th Floors

Designer Approval

N

PROJECT LOCATION

Planning • Interior Design

119 Brookstown Avenue Suite 100 • Winston-Salem NC 27101 • cjmw.com • 336.724.1503

Winston-Salem, NC • Raleigh, NC • Lynchburg, VA

August 21, 2017 The University of North Carolina at Chapel Hill Department of Facilities Planning + Design Jerry U. Guerrier, RA, LEEDTM AP Assistant Director 103 Airport Drive Campus Box #1090 Chapel Hill, North Carolina 27599-1090

Dear Mr. Guerrier, On behalf of my team at CJMW Architecture (CJMW), I am excited to submit our qualifications for the renovations in the Kenan Center and McColl Building. We know these buildings well – I personally have been the lead interior designer for the firm’s work with Kenan-Flagler for more than 15 years. Our team has worked in both the McColl building and the Kenan Center on multiple projects, most of which involved administrative space. We have also recently completed multiple projects at the Rizzo Conference Center, including the Phase III addition and renovations, which included administrative and conference spaces. In addition to experience working with the Kenan-Flagler Business School, CJMW has extensive experience in the renovation of business and administrative spaces. Our 12-person Interior Design Studio includes designers, a licensed architect, a Studio-dedicated BIM technician, and additional technical design support. We handle projects of all scales, from FFE for small spaces up to and including large scale corporate and hospitality project design. Information about our relevant experience as well as the proposed team can be found in the following pages of the Executive Summary as well as the SF330 submittal. We appreciate your consideration of our team and look forward to the opportunity to discuss our qualifications and the project in more depth. Sincerely yours, Kathleen Warner

Principal • Director, Interior Design Studio

F. EXAMPLE PROJECTS WHICH BEST ILLUSTRATE PROPOSED TEAM'SQUALIFICATIONS FOR THIS CONTRACT

(Present as many projects as requested by the agency, or 10 projects, if not specified. Complete one Section F for each project.)

a. PROJECT OWNER

21. TITLE AND LOCATION (City and State)

25. FIRMS FROM SECTION C INVOLVED WITH THIS PROJECT

20. EXAMPLE PROJECT KEY NUMBER

a.

b.

c.

d.

e.

f.

(1) FIRM NAME (2) FIRM LOCATION (City and State)

(3) ROLE(1) FIRM NAME (2) FIRM LOCATION (City and State)

(3) ROLE(1) FIRM NAME (2) FIRM LOCATION (City and State)

(3) ROLE(1) FIRM NAME (2) FIRM LOCATION (City and State)

STANDARD FORM 330 (REV. 8/2016) PAGE 3

(3) ROLE

(1) FIRM NAME (2) FIRM LOCATION (City and State) (3) ROLE

23. PROJECT OWNER'S INFORMATION

(3) ROLE(1) FIRM NAME (2) FIRM LOCATION (City and State)

22. YEAR COMPLETEDPROFESSIONAL SERVICES CONSTRUCTION (If applicable)East 54 Phase I & II

Chapel Hill, NC

UNC Kenan-Flagler Business School

CJMW Architecture Architecture (phase II), Interior Design (phase I & II)

A/V Systems Design (Phase I only)

Winston-Salem, NC

Durham, NCKONTEK systems, inc.

24. BRIEF DESCRIPTION OF PROJECT AND RELEVANCE TO THIS CONTRACT (Include scope, size, and cost)

For the off-campus offices of Kenan-Flagler Business School’s program development, marketing and Online MBA school departments, CJMW Architecture designed a collaborative and contemporary space that reflects the less traditional team and program focus of the online MBA program. Blending modern forms with traditional finishes, the tenant upfit responds to the client’s need for collaborative, open and private office space. Several years later, the team upfit additional space for another MBA program division using a similar aesthetic. After seeing the benefit of the CJMW Architecture-designed glass-walled offices used in another division, the East 54 team opted for an aluminum framed glass wall system to keep the offices visually open and allow light to infuse the entire space. Carpet in the private offices carries through into the open office area; this texture plus rich wood finishes bring a balance to the harder, industrial feel of the concrete floors and open ceilings. Mechanical systems supporting the entire building are located in the East 54 space; ceiling planes mask the systems and provide a connective link between individual spaces.

b. POINT OF CONTACT NAME

PI: Roger Perry / PII: Amy Wittmayer

03

c. POINT OF CONTACT TELEPHONE NUMBER

PI: 919.929.0660 / PII: 919.962.3593

I - 2011 / II - 2015 I - 2011 / II - 2015

F. EXAMPLE PROJECTS WHICH BEST ILLUSTRATE PROPOSED TEAM'SQUALIFICATIONS FOR THIS CONTRACT

(Present as many projects as requested by the agency, or 10 projects, if not specified. Complete one Section F for each project.)

a. PROJECT OWNER

21. TITLE AND LOCATION (City and State)

25. FIRMS FROM SECTION C INVOLVED WITH THIS PROJECT

20. EXAMPLE PROJECT KEY NUMBER

a.

b.

c.

d.

e.

f.

(2) FIRM LOCATION (City and State)

(3) ROLE(1) FIRM NAME (2) FIRM LOCATION (City and State)

(3) ROLE(1) FIRM NAME (2) FIRM LOCATION (City and State)

(3) ROLE(1) FIRM NAME (2) FIRM LOCATION (City and State)

STANDARD FORM 330 (REV. 8/2016) PAGE 3

(3) ROLE

(1) FIRM NAME (2) FIRM LOCATION (City and State) (3) ROLE

b. POINT OF CONTACT NAME

23. PROJECT OWNER'S INFORMATION

c. POINT OF CONTACT TELEPHONE NUMBER

(3) ROLE(1) FIRM NAME (2) FIRM LOCATION (City and State)

22. YEAR COMPLETEDPROFESSIONAL SERVICES CONSTRUCTION (If applicable)Rizzo Conference Center Phase III

Chapel Hill, NC

UNC Kenan-Flagler Business School

CJMW Architecture Architecture, Interior Design

MEP & Fire Protection Engineering

MEP & Fire Protection Engineering

Winston-Salem, NC

Raleigh, NC

Raleigh, NC

(1) FIRM NAME

Barrett, Woodyard & Associates, Inc.

RDK Engineers

24. BRIEF DESCRIPTION OF PROJECT AND RELEVANCE TO THIS CONTRACT (Include scope, size, and cost)

Placed in connection with the existing residence hall, the 93,000 square foot, 5-story addition blends integrally into its surroundings and creates a dynamic new gathering place for the whole campus. A curved terraced section links new to old, forming a semi-enclosed courtyard that will be the outdoor social heart of the Rizzo Center campus. The executive lounge, fitness center, classrooms and other public areas on the courtyard level open directly onto the outdoor meeting and recreation spaces, enlivening and energizing the outdoor space. Additional renovations and refreshes of existing spaces were also a part of the overall effort. CJMW Architecture’s interior design team drew from their hospitality design experience to bring a fresh and updated interpretation for the guest room designs. The project is LEED Silver-targeted.

Brent Haste

04

800.727.5531

2015 2016

KONTEK systems, inc. Durham, NC A/V Systems Design

ATTACHMENT I

DESIGNER SELECTION – MARSICO HALL MEP SYSTEMS PROJECT

This project will focus on improvements to the complex and highly integrated building mechanical, electrical, specialty lab and medical equipment, and control systems in Marsico Hall. This project will review adequacy of building system capacity, including required redundancy; power quality issues; and critical points of failure that have significant impact of the medical imaging function. Recommendations for mechanical, plumbing and electrical improvements will be reviewed with stakeholders and implemented as part of the project. The design team will provide a report summarizing findings of the investigative phase and recommendations. The project budget is $600,000 and will be funded by State appropriations.

This project was advertised on July 14, 2017. Six (6) proposals were received. Three (3) firms were interviewed on August 22, 2017. Members of the Board of Trustees did not participate in the interviews.

The committee recommended the selection of the three firms in the following priority order:

1. Newcomb & Boyd Atlanta, GA

2. RMF Raleigh, NC

3. McKim & Creed Raleigh, NC

The firms were selected for their past performance on similar projects, the strength of their project team members, and experience with campus projects.

RECOMMENDED ACTION:

A motion to approve the three firms in the following priority order:

1. Newcomb & Boyd Atlanta, GA

2. RMF Raleigh, NC

3. McKim & Creed Raleigh, NC

Marsico Hall MEP Systems (CIP 663)

Designer Approval

2006 CAMPUS MASTER PLAN

N

PROJECT LOCATION

Designer Approval

CAMPUS MAP

N

PROJECT SITE

Marsico Hall MEP Systems (CIP 663)

F. EXAMPLE PROJECTS WHICH BEST ILLUSTRATE PROPOSED TEAM’S QUALIFICATIONS FOR THIS CONTRACT

(Present as many projects as requested by the agency, or 10 projects, If not specified. Complete one Section F for each project.)

20. EXAMPLE PROJECT KEY NUMBER

1

21. TITLE AND LOCATION (City and State)

University of North Carolina at Chapel Hill Marsico Hall Chapel Hill, North Carolina

22. YEAR COMPLETED

PROFESSIONAL SERVICES

2011

CONSTRUCTION (if Applicable)

2014

23. PROJECT OWNER’S INFORMATION

a. PROJECT OWNER

University of North Carolina at Chapel Hill b. POINT OF CONTACT NAME

Greg Graves

c. POINT OF CONTACT TELEPHONE NUMBER

919-843-5659

24. BRIEF DESCRIPTION OF PROJECT AND RELEVANCE TO THIS CONTRACT (Include scope, size, and cost)

Marsico Hall is a high-rise research facility including laboratories for drug discovery and delivery, a vivarium housing 3,000 small and 18 large animal cages, general wet laboratories, a USP 797 cleanroom, and a campus district energy plant. Marsico Hall houses many of the School of Medicine's and the Eshelman School of Pharmacy's research programs, including the Marsico Lung Institute, the Biomedical Research Imaging Center, and researchers from the Lineberger Comprehensive Cancer Center, nanomedicine, microbiology and immunology, and pharmaco-engineering. Underground chilled water piping work includes the replacement of 800 linear feet of 24" chilled water mains and a new 18" connection to the Lineberger Comprehensive Cancer Center. Imaging equipment located in the facility includes a cyclotron, a small bore 9T MRI, a 3T MRI, MR/PET, PET/CT, and multiple NMRs. Sustainable features include a district energy plant with heat recovery chillers, a runaround loop energy recovery system, variable volume laboratory controls, a non-potable water system, low flow plumbing fixtures, and laboratory equipment water saving options. This building is pursuing LEED Silver certification. 343,000 square feet, $153,884,220 construction cost.

25. FIRMS FROM SECTION C INVOLVED WITH THIS PROJECT

a.

(1) FIRM NAME

(2) FIRM LOCATION (City and State)

Atlanta, GA

(3) ROLE

Mechanical, Electrical, Plumbing, Fire Protection, Audio-Visual, Communications, Security

STANDARD FORM 330 (REV. 08/2016) PAGE 3

F. EXAMPLE PROJECTS WHICH BEST ILLUSTRATE PROPOSED TEAM’S QUALIFICATIONS FOR THIS CONTRACT

F. EXAMPLE PROJECTS WHICH BEST ILLUSTRATE PROPOSED TEAM’S QUALIFICATIONS FOR THIS CONTRACT

(Present as many projects as requested by the agency, or 10 projects, If not specified. Complete one Section F for each project.)

20. EXAMPLE PROJECT KEY NUMBER

9

21. TITLE AND LOCATION (City and State)

New Orleans BioInnovation Center Retrocommissioning New Orleans, Louisiana

22. YEAR COMPLETED

PROFESSIONAL SERVICES

2016

CONSTRUCTION (if Applicable)

2016

23. PROJECT OWNER’S INFORMATION

a. PROJECT OWNER

New Orleans BioInnovation Center, Inc.

b. POINT OF CONTACT NAME

Aaron Miscenich

c. POINT OF CONTACT TELEPHONE NUMBER

504-680-2973

24. BRIEF DESCRIPTION OF PROJECT AND RELEVANCE TO THIS CONTRACT (Include scope, size, and cost)

Retrocommissioning of an incubator facility housing laboratory space, office space, and meeting and conference rooms. 66,500 square feet.

25. FIRMS FROM SECTION C INVOLVED WITH THIS PROJECT

a.

(1) FIRM NAME

(2) FIRM LOCATION (City and State)

Atlanta, GA

(3) ROLE

Commissioning

STANDARD FORM 330 (REV. 08/2016) PAGE 3

PROJECTS WHICH BEST ILLUSTRATE PROPOSED TEAM’S QUALIFICATIONS FOR THIS CONTRACT

{00102442.DOCX 2}

ATTACHMENT J

APPROVAL FOR PROPERTY DEMOLITION – 2311 HOMESTEAD ROAD

This request is for approval to demolish the fire-damaged house as well as the ancillary structures (barn and shed) located at 2311 Homestead Road in Chapel Hill. The existing residential structure was destroyed by fire on April 19, 2017 and is damaged beyond repair. The 2311 Homestead Road property was originally acquired in 1992 for the purpose of providing additional frontage and access to Carolina North along Homestead Road.

RECOMMENDED ACTION

A motion to approve the demolition of all structures at 2311 Homestead Road in Chapel Hill, North Carolina.

House

Barn &Shed

Carolina North

Homestead Road

100Feet ¯

2311 Homestead Road

MLK Jr. Blvd.

CarolinaNorth

Homestead Rd

Franklin St

Central CampusUNC

2311 Homestead Rd

NC 54

15/50

1 BYP

NC 54Sources: Esri, HERE, DeLorme, TomTom, Intermap,increment P Corp., GEBCO, USGS, FAO, NPS, NRCAN,GeoBase, IGN, Kadaster NL, Ordnance Survey, EsriJapan, METI, Esri China (Hong Kong), swisstopo,MapmyIndia, © OpenStreetMap contributors, and the GISUser Community

14 September 2017

PPAB 3863651V1

ATTACHMENT K

SPECIAL OBLIGATION BOND PROJECT

The General Statutes permit the Board of Governors to issue special obligation bonds payable from obligated resources to fund the costs of acquiring, constructing or providing a special obligation project at any of the constituent institutions of the University of North Carolina. The General Statutes require the Board of Trustees of The University of North Carolina at Chapel Hill to approve the issuance of the bonds for its special obligation bond projects. Attached is a resolution authorizing the issuance of special obligation bonds for self-liquidating projects recently approved by the North Carolina General Assembly

RECOMMENDED ACTION:

A motion to approve the attached resolution.

ATTACHMENT L

REPORT TO THE FINANCE,INFRASTRUCTURE, AND

AUDIT COMMITTEE OF THE

BOARD OF TRUSTEES

Internal Audit Department

University of North Carolina at Chapel Hill

September 27, 2017

UNC - CHAPEL HILL INTERNAL AUDIT DEPARTMENT

SUMMARY OF AUDIT ACTIVITIES AND PROJECTS COMPLETED AND IN PROCESS APRIL 17 TO AUGUST 6, 2017

Page 1 of 3

STAFFING UPDATE Andrew Baker joined the Internal Audit staff on June 19, 2017. He previously worked with the Office of the State Auditor in its Performance and Investigative Audit units. He holds a Masters of Accounting degree for NC State and is a Certified Fraud Examiner. This year, we plan to make use of the State of North Carolina’s Internal Audit Staffing Services term contract to obtain additional resources for audit projects. COMPLETED PROJECTS Facilities Use of Consortiums – review of potential for use of repair and renovations services procured under the National Joint Powers Alliance (NJPA). We determined that the NJPA is an allowed source for repair and renovations services. Management agreed to consider using the NJPA as an alternative for future projects. School of Government – Development Finance Initiative – review of contracts and the relationship between the School and an outside entity that provides redevelopment project management services. This review identified undisclosed conflicts of interest and commitment and advance payment for ser-vices. The School no longer uses the outside entity that was the focus of this audit and has implemented a new process for providing redevelopment services to its clients. Management agreed to discontinue the prac-tice of paying for goods and services in advance. The individual with the conflicts of interest and com-mitment has since left the University. Carolina Center for Education Excellence (CCEE) – management request – an assessment of finan-cial matters related to a community program run by the School of Education including revenue levels and matching of revenue and costs. We found that some expenses for this program were charged to other sources of funds rather than revenue the program generated. Management responded that they discontinued the program that was the focus our review and all of the CCEE’s other revenue producing programs. Management also committed to taking steps to ensure that, in the future, costs are charged to the appropriate sources of funds. School of Law - Center for Civil Rights – Assistance to management in reviewing allocations of shared costs. Our review determined that the method that the School of Law used to allocate shared costs to the Center for Civil Rights was reasonable and accurate. School of Law – Teaching Loads – review of allegations that faculty teaching loads were not in keeping with School policy. We reviewed teaching loads for all School of Law faculty members since academic year 2006/07 and determined that all faculty teaching loads were in compliance with School policy.

UNC - CHAPEL HILL INTERNAL AUDIT DEPARTMENT

SUMMARY OF AUDIT ACTIVITIES AND PROJECTS COMPLETED AND IN PROCESS APRIL 17 TO AUGUST 6, 2017

Page 2 of 3

We concluded that the allegations did not have merit. However, we found occasional differences be-tween the School’s records and the Academic Personnel Office’s records for faculty members who were on extended leave. We also identified opportunities to clarify language in the School’s Faculty Refer-ence Manual. School management agreed to resolve these issues. Anesthesiology 2017 – assistance to management in following-up on allegations referred by the Office of the State Auditor. We worked with management of the Department of Anesthesiology (Department) and determined that the allegations did have merit. We will provide the Department with a summary of the results of the review. There will not be a formal audit report. IN PROCESS Follow-up of Prior Internal Audit Findings – a review and evaluation of steps that management has taken to resolve issues reported from past audits. Standard 2500 – Monitoring Progress of the Inter-national Standards for the Professional Practice of Internal Auditing requires that “the chief audit ex-ecutive must establish and maintain a system to monitor the disposition of results communicated to management.” This year, we will take a different approach to reporting the results of our follow-up work. We will issue a separate follow-up report for each prior audit with findings that have not been corrected as of April 30, 2017. In the past, we issued only one summary follow-up report that identified unresolved items, only. Indi-vidual follow-up reports will provide more complete information about the status of prior findings by identifying audits that have been cleared as well as those with unresolved issues. At any point in time, we can provide a report of all unresolved findings. Historically Under-utilized Business Program – a review of processes used to promote and encourage full and open competition, promote equal access to contracting opportunities among the various con-tractors and vendors that do business with the University, and ensure compliance with policy reporting requirements related to this program. This project has been delayed by time-sensitive projects requested by management. Nutrition Research Institute – a review of allegations of incorrect purchasing practices and use of requisitions when needed. We have expanded the scope of this review to include a wider range of fiscal activities at the Institute. Internal control work is in process. Clery Act Reporting – a review of processes used to manage notifications and reporting required by the “Jeanne Clery Disclosure of Campus Security Policy and Campus Crime Statistics Act”. This pro-ject has been delayed by the Nutrition Research Institute review and work done to assess the status of prior audit findings.

UNC - CHAPEL HILL INTERNAL AUDIT DEPARTMENT

SUMMARY OF AUDIT ACTIVITIES AND PROJECTS COMPLETED AND IN PROCESS APRIL 17 TO AUGUST 6, 2017

Page 3 of 3

Lineberger Comprehensive Cancer Center Tissue Culture Facility – a review of allegations regard-ing camera and computer purchases made by the Tissue Culture Facility. ON-GOING ADVISORY PROJECTS AND COMMITTEE WORK • AICPA Business Environment and Concepts Subcommittee (CPA examinations); • Data Analytics Committee – team of internal auditors that will work to identify and develop data

analytics tools and techniques; • HIPAA Privacy Liaisons; • University-wide Committee on the Protection of Personal Data; • Policy Liaisons; • Compliance Strategy Committee; and • Multiple short-term projects done to assist management with identifying and managing risks.

Hours VarianceBudgeted Charged (Over)/Under

Total Hours Available -1- 14,560 n/a n/aLess: Vacancies -2- (3,640) 5200 1,560Less: Training & Professional Development (420) 712 (292)Less: Leave (2,341) 1,438 903 -a-Less: Other Administrative Time -3- (1,240) 1,146 94 -a-

Total for Training, Leave, & Administrative 4,001 8,496

Hours Available for Projects 6,919

Routine Audits 1,625 527 1,098 -b-Annual Projects 1,200 1,728 (528)Audit Related -4- 1,580 1,207 373Unplanned Projects and Advisory Work 2,800 2,728 72

Total Scheduled/Charged 7,205 6,190

Under/<Over> Scheduled (286)

-1- = seven staff members at 2080 hours/year-2- = one vacancy projected to be filled by 09/30/16; another to be filled by end of calendar year; one position projected to be left vacant due to lack of funding. Actual was one position filled in January 2017, one filled in June 2017, and two vacant for full year.-3- = meetings, professional reading, and other office activities

-4- = consulting and advisory work, activities that improve audit operations.-a- = fewer hours due to vacancies

-b- = fewer hours due to vacancies and time spent on audit follow-ups

UNC Internal AuditUse of Audit Resources

Summary of Audit Hours Used - FY 2017 as of 06/30/17

UNC Internal Audit2016/17 Audit Schedule as of June 30, 2017

Page 1 of 2

Planned Audits

Complete

Assistance with 2017 OSA IT General Controls Audit new

In Process - will continue in FY 2017/18

Historically Underutilized Business ProgramClery Act Reporting

Carried-Forward to FY 2017/18

Governance - Trustee Orientation

Cancelled

Export Controls - deferred past FY 2017/18, University is recruiting for Export Controls OfficerAccess Revocation - replaced with assistance with OSA IT audit

Annual Projects

Complete

2016/17 Risk Assessment and Audit Plan2016 State AuditUNC Business Compliance Program 20172016 OSA Federal Compliance Auit Follow-up2nd Follow-up - 2015 OSA Financial Statement AuditEnterprise Resource Planning

In Process - will continue in FY 2017/18

Follow-up for Prior Internal Audit Findings2017/18 Risk Assessment and Audit Plan

Audit Related

Complete

SACS 2016HIPAA Risk AssessmentUNCAA Conference Planning

Carried-Forward to FY 2017/18

Internal QAR

On Going

Audit ManualTime SystemOffice SystemsAudit PlanningAudit CommitteeMedia RequestsAudit Process ImprovementIT Governance Committee & Data Custodian WorkCERTIFKPI ReportingBoard of Governors' MeetingsHIPAA Security LiaisonContinuous AuditingUniversity Committee on the Protection of Personal DataPrivacy Liaison

Special Projects & Management Requests

CompleteOrthodonticsAuxiliary Equipment (referral from Office of State Auditor)

UNC Internal Audit2016/17 Audit Schedule as of June 30, 2017

Page 2 of 2

Lineberger Cancer Center Grants (referral from Office of State Auditor)Health BehaviorLaw - TravelMaternal and Infant HealthNC Institute of Public Health - assistance to managementGene Therapy 2016- assistance to managementNeurology - NIH Radiology 2016School of GovernmentLaw - EPAPFacilities Use of ConsortiumsAnesthesiology 2017CommunicationsHealth Behavior Advances - assistance to managementRadiology Follow-up

In Process - will continue in FY 2017/18Carolina Center for Education ExcellenceCenter for Civil RightsLaw - Teaching LoadsNutrition Research InstituteLineberger Cancer Center Tissue Culture Facility

Multiple Short-term Advisory Projects

1. Introduction

UNC General Administration Petition Regarding Political Activity

SECTION A: INTRODUCTION, DEFINITIONS, AND INSTRUCTIONS

Under Section 300.5.2 of the UNC Policy Manual, an employee who is exempt from the State Human Resources Act (an "EHRA employee") must submit this petition for review before becoming a candidate for or accepting an appointive or elective public office.

2. Relevant Definitions1

a. "Appointive public office" means a public office that is filled or obtained by means other than an election.

b. "Conflict of commitment" relates to an individual's distribution of time and effort between obligations to University employment and participation in other activities outside ofUniversity employment. A conflict of commitment occurs when the pursuit of such outside activities involves an inordinate investment oftime or is conducted at a time that interferes with the employee's fulfillment of University employment responsibilities.

c. "Conflict of interest" means situations in which financial or other personal considerations, circumstances, or relationships may compromise, may involve the potential for compromising, or may have the appearance of compromising, an employee's objectivity in fulfilling their University duties or responsibilities, including research, service, teaching activities, and administrative duties.

d. "Elective public office" means a public office that is filled or obtained through the results ofan election.

e. "Full-time employee" means an individual who is employed by the University at least three-quarter (3/4) time, including faculty who are employed on a nine-month per calendar year basis.

f. "Major public office" means (1) any public office requiring full-time service, regardless of the amount o f compensation; (2) any public office requiring service on a part-time basis for which compensation is more than nominal2; or (3) membership in the North Carolina General Assembly.

g. "Minor public office" means any public office that is not a major public office.h. "Part-time employee" means an individual who is employed but who is not a full-time

employee.i. "Public office" means any national, state, or local governmental position of public trust and

responsibility, whether elective or appointive, which is created, prescribed, or recognized by constitution, statute or ordinance (other than within the University of North Carolina).

3. Instructions for Completing Section B of the Petition

The table on the following page specifies which portions of Section B the petitioner must complete.Petitioners also should read Section 300.5.2 in its entirety to ensure they are aware of all applicable requirements and deadlines.

1 The definitions in Sections 300.5.1 and 300.5.2 of the UNC Policy Manual are incorporated herein by reference. 2 In this context, "compensation which is more than nominal" means actual annual compensation or expected annual

compensation, whichever is greater, in excess of$10,000, excluding direct reimbursements for expenses incurred by the officeholder incident to holding office, whether such expenses are calculated on a per diem basis or an actual expense basis.

Rev 11-01-2016 Page I of6

ATTACHMENT M

9/28/2017(Chairman)

The University of North Carolina at Chapel HillEXECUTIVE SUMMARY

Board of TrusteesSept 28, 2017

Appendix A

Page 1

No. College/Division Name Dept./School Current Rank New Rank Tenure Request Reason Effective Date Salary

1 Health Affairs Mirnela Byku Medicine Nominated Clinical Assistant Professor Assistant Professor 10/1/2017 $220,000.00

2 Health Affairs Melissa Gilkey Health BehaviorNominated Clinical Assistant Professor Assistant Professor 10/1/2017 $99,000.00

1 Health Affairs Arlene Chung Medicine/Pediatrics Assistant Professor Assistant Professor 10/1/2017 $168,000.00

0Promotion to Full Professor

1 Health Affairs Carol Golin Medicine/Health Behavior Associate Professor Professor 11/1/2017 $183,565.002 Health Affairs Gretchen Stuart OB-GYN Associate Professor Professor 9/1/2017 $227,000.00

Reappointments to the same Rank0

Designation/Reappointments to Departmental Chair0

Designation/Reappointments to Distinguished Professorship

1 Health Affairs Henrik Dohlman Pharmacology Professor/ChairSanford Steelman Distinguished Professor 9/29/2017 $180,500.00

2 Academic Affairs Sarah Verbiest Social Work Clinical Associate Professor John A. Tate Early Career Scholar 10/1/2017 $102,975.00

3 Academic Affairs Lisa Zerden Social Work Clinical Associate Professor John A. Tate Early Career Scholar 10/1/2017 $97,681.00

Actions Conferring TenurePromotion Conferring Tenure

0New Appointments Conferring Tenure

0Addition of Joint Appointment Conferring Tenure

0Corrections

1 Academic Affairs Kara Millonzi* Government Professor Albert and Gladys Coates Distinguished Term Professor 9/1/2017

Personnel ActionsNew Appointments without Tenure

Addition of Joint Appointment without Tenure

Departmental Transfer

ATTACHMENT N

The University of North Carolina at Chapel HillEXECUTIVE SUMMARY

Board of TrusteesJuly 14, 2014

Appendix B

Page 2

No. College/Division Name School Department Rank Reason

Requested Amount of Increase **

Percent of Increase **

June 30 Salary

Current Salary New Salary *

Effective Date

1 Academic Affairs Ann Anderson Government Associate ProfessorIncrease due to new appointment as Albert and Gladys Coates Term Associate Professor $9,203 7.65% $120,319 $123,522 $129,522 9/1/2017

2 Health Affairs Soumya Benbhabbour Medicine Biomedical Engineering Research Assistant Professor

Increase due to new primary appointment as Tenure-Track Assistant Professor via external competitive event $35,030 41.23% $84,970 $84,970 $120,000 9/1/2017

3 Health Affairs Alison Brenner Medicine Medicine Research AssociateIncrease due to new appointment as Research Assistant Professor via external competitive event $18,935 26.27% $72,065 $75,661 $91,000 10/1/2017

4 Health Affairs Kimberley Brownley Medicine Psychiatry Research Associate Professor

Increase due to new secondary administrative appointment as Director of the NC TraCS Regulatory Support Program $25,003 29.99% $83,382 $88,385 $108,385 10/1/2017

5 Health Affairs Thomas Caranasos Medicine Surgery Assistant Professor/Director

Increase due to new secondary appointments as Surgical Director of the McAllister Heart Institute, and as Surgical Lead for the structural heart program in the SOM $60,000 18.65% $445,000 $468,000 $528,000 9/1/2017

6 Health Affairs Stephen Eckel Pharmacy PACE Clinical Associate ProfessorIncrease due to new secondary appointment as Interim Department Chair $10,000 5.74% $174,350 $174,350 $184,350 9/1/2017

7 Health Affairs Rebecca Fry Public HealthEnvironmental Sciences & Engineering Professor

Increase due to retetion counteroffer as Dr. Fry has received a formal offer from Rutgers University. $114,284 92.75% $123,216 $135,538 $237,500 11/1/2017

8 Health Affairs David Gerber Medicine Surgery Professor/ChiefIncrease due to new secondary appointment as Vice Chair $80,106 19.03% $395,894 $471,000 $501,000 10/1/2017

9 Academic Affairs Willow Jacobson Government Professor

Increase due to new appointment as Albert and Gladys Coates Term Professorship for Teaching Excellence $10,709 8.85% $120,942 $125,651 $131,651 9/1/2017

10 Academic Affairs Diane Juffras Government Professor

Increase due to new appointment as Albert and Gladys Coates Term Professorship for Teaching Excellence $8,332 6.26% $133,160 $135,492 $141,492 9/1/2017

11 Academic Affairs Kara Millonzi Government Professor

Increase due to new appointment as Albert and Gladys Coates Term Professorship for Teaching Excellence $10,858 8.00% $135,766 $140,624 $146,624 9/1/2017

12 Academic Affairs Kim Nelson Government Associate ProfessorIncrease due to new appointment as Albert and Gladys Coates Term Associate Professor $9,684 8.18% $118,368 $122,052 $128,052 9/1/2017

13 Health Affairs Ellen O'Shaughnessey Medicine Pharmacology Post Doc Research AssociateIncrease due to new appointment as Research Assistant Professor via external competitive event $14,500 30.21% $48,000 $52,140 $62,500 9/1/2017

14 Health Affairs Carl Seashore Medicine Pediatrics Clinical ProfessorIncrease due to new administrative appointment as Director of Pediatric Informatics Innovation $33,067 17.98% $183,912 $196,979 $216,979 10/1/2017

15 Health Affairs Kavita Singh Ongechi Public Health Maternal and Child Health Associate Professor

Increase due to new appointment as Associate Professor (Tenure Track) via external competitive event $26,150 22.38% $116,850 $116,850 $143,000 11/1/2017

16 Academic Affairs Meredith Smith Government Assistant ProfessorIncrease due to new appointment as Albert Coates Distinguished Term Assistant Professor $9,503 9.48% $100,255 $103,758 $109,758 9/1/2017

17 Academic Affairs Charles Szypszak Government ProfessorIncrease due to new appointment as Albert Coates Distinguished Professor $14,528 9.51% $152,767 $155,295 $167,295 9/1/2017

18 Health Affairs Jennifer Tang Medicine OB/GYN Assistant Professor Increase due to internal equity $15,514 9.99% $155,295 $155,295 $170,809 10/1/2017

19 Health Affairs Katherine Tumlinson Public Health Maternal and Child Health Post Doc Research AssociateIncrease due to new appointment as Assistant Professor via external competitive event $49,000 73.13% $67,000 $67,000 $116,000 9/1/2017

20 Academic Affairs Sarah Beth Verbiest Social Work

Clinical Associate Professor/Director/Adjunct Assistant Professor

Increase due to new appointment as John A Tate Early Career Scholar for Children in Need $20,500 20.50% $99,976 $112,976 $120,476 10/1/2017

21 Academic Affairs Lisa Zerden Social WorkClinical Associate Professor/Senior Associate Dean

Increase due to new appointment as John A Tate Early Career Scholar for Children in Need $15,142 15.14% $100,039 $107,681 $115,181 10/1/2017

22232425

No. College/Division Name Department/School Rank Reason

Total Monetary Value of Non-

Salary Compensation

Duration of Non-Salary

Compensation Effective Date End Date

Non-Salary Compensation Actions0 N/A N/A N/A N/A N/A N/A N/A N/A N/A NA

Compensation Actions*Available funding for each action has been confirmed by the appropriate Department and School/Division management officials to support the proposed salary increase. Upon implementation, specific funding sources are reviewed and approved at the Department level, as well as by the applicable University Central financial offices, including the University Budget Office and the Office of Sponsored Research for grant-funded salaries.

** Based on cumulative increase(s) to 6/30 salary

The University of North Carolina at Chapel HillEXECUTIVE SUMMARY

Board of TrusteesJuly 14, 2014

Appendix C

Page 3

No. College/Division Name Department/School Rank Description

0 N/A N/A N/A N/A N/A

For Information

No. College/Division Name Department/School Rank Reason

Requested Increase Amount

Percent of Increase

Current Salary New Salary

Effective Date

No. College/Division Name Department/School Rank Reason

Total Monetary

Value of Non-Salary

Compensation

Duration of Non-Salary

Compensation

Effective Date End Date

1 N/A N/A N/A N/A N/A N/A N/A N/A N/A NA

Compensation Actions

Non-Salary Compensation Actions